(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 March 2011 (03.03.2011)

PCT

(10) International Publication Number
WO 2011/022838 A1

(51) **International Patent Classification**:
C07J 9/00 (2006.01) ***A61P 1/16*** (2006.01)
A61K 31/575 (2006.01)

(21) **International Application Number**:
PCT/CA2010/001338

(22) **International Filing Date**:
25 August 2010 (25.08.2010)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/236,750 25 August 2009 (25.08.2009) US

(63) **Related by continuation (CON) or continuation-in-part (CIP) to earlier application**:
US 61/064,280 (CIP)
Filed on 26 February 2008 (26.02.2008)

(71) **Applicant** *(for all designated States except US)*: **BRITISH COLUMBIA CANCER AGENCY BRANCH** [CA/CA]; 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3 (CA).

(72) **Inventors; and**
(75) **Inventors/Applicants** *(for US only)*: **LING, Victor** [CA/CA]; 5671 Trafalgar Street, Vancouver, Bristish Columbia V6N 1C2 (CA). **WANG, Renxue** [CA/CA]; 6210 Logan Lane, Vancouver, British Columbia V6T 2K9 (CA). **SHEPS, Jonathan Ahab** [CA/CA]; 217-518 Moberly Road, Vancouver, British Columbia V5Z 4G3 (CA).

(74) **Agents**: **CHATTERJEE, Alakananda, Ph.D.** et al.; Gowling Lafleur Henderson LLP, P.O. Box 30, Suite 2300, 550 Burrard Street, Vancouver, British Columbia V6C 2B5 (CA).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2011/022838 A1

(54) **Title**: POLYHYDROXYLATED BILE ACIDS FOR TREATMENT OF BILIARY DISORDERS

(57) **Abstract**: The invention provides, in part, polyhydroxylated bile acids for treating biliary disorders, for example, biliary disorders arising out of cholestasis or portal hypertesion. The invention also provides, in part, polyhydroxylated bile acids for stimulating bile flow. New compounds 2α,3α,7α,12α-tetrahydroxy-5β-cholanoic acid and 3α,4α,7α,12α-tetrahydroxy-5β-cholanoic acid are disclosed, uses thereof and synthesis thereof.

POLYHYDROXYLATED BILE ACIDS FOR TREATMENT OF BILIARY DISORDERS

FIELD OF INVENTION

[0001] The present invention provides polyhydroxylated bile acids and derivatives thereof to treat biliary disorders or stimulate bile flow. More specifically, the present invention provides polyhydroxylated bile acids and derivatives thereof to treat biliary disorders leading to, or associated with, cholestasis or portal hypertension, or to stimulate bile flow.

BACKGROUND OF THE INVENTION

[0002] Bile is a complex secretion produced by the liver. It is stored in the gall bladder and periodically released into the small intestine to aid in digestion. Bile components include cholesterol, phospholipids, bile pigments, and various toxins that the liver eliminates through biliary/fecal exclusion. Bile salts are synthesized and actively secreted across canalicular membranes providing the osmotic force to drive the flow of bile. This is the rate-limiting step for bile formation. Bile flow is essential for liver detoxification, digestion, cholesterol metabolism, and absorption of lipid-soluble nutrients and vitamins.

[0003] Bile acids are critical as carriers for elimination of cholesterol from the body through biliary secretion and as a detergent for the ingestion of fatty acids and fat-soluble vitamins (23). Bile acids also play important roles in regulating cell apoptosis/survival (37; 38; 39; 40; 41) and in regulating gene expression through the farnesoid X-activated receptor (42; 43; 44; 45; 46; 47) in hepatocytes. Bile acids are synthesized in hepatocytes from cholesterol, secreted into the bile after being conjugated with glycine or taurine, reabsorbed in the small intestine, and recirculated back to hepatocytes through the portal vein. Canalicular secretion of bile acids from liver into the bile is a key process in the enterohepatic circulation of bile acids and its malfunction results in different hepatic diseases (23). If this process is disrupted, accumulation of bile acids often causes liver damage due to detergent effects. In humans, the bile acid pool circulates 6-10 times every 24 h, resulting in daily bile salt secretion of 20-40 g in about 400 ml (51; 49).

[0004] Common bile acids found in the bile of selected mammals include the following:

Bile acid skeleton



R'''' – taurine or glycine



Glycine



Taurine

Common Name	R'	R''	R'''	Commonly found in species
Cholic acid (3α7α12α)	α -OH	α -OH	H	bear, cat, hamster, human, mouse, pig, rabbit, rat
Chenodeoxycholic acid (3α7α)	α -OH	H	H	bear, hamster, human, pig
Deoxycholic acid (3α12α)	H	α -OH	H	cat, human, rabbit
Ursodeoxycholic acid (3α7β)	β -OH	H	H	bear
Lithocholic acid (3α)	H	H	H	human, rat, mouse
β-muricholic acid (3α6β7β)	β -OH	H	β -OH	mouse, rat
α-muricholic acid (3α6α7β)	α -OH	H	β -OH	pig, mouse, rat
Ω-muricholic acid (3α6α7α)	β -OH	H	α -OH	mouse, rat

[0005] Bile Salt Export Protein (BSEP, ABCB11, or Sister of P-glycoprotein (SPGP)), a bile canalicular ATP-binding cassette (ABC) protein, has been identified as the main transport system for the biliary secretion of bile acids (50; 13). BSEP mutations in humans lead to impaired bile salt secretion and a severe liver disease, progressive familial intrahepatic cholestasis type 2 (PFIC2) (1, 2) . Bile acid secretion in PFIC2 patients is usually less than 1% of normal (2).

BSEP has also been implicated as being a target for drugs that cause cholestasis (3-6). BSEP mutations have also been associated with chronic intrahepatic cholestasis, benign recurrent intrahepatic cholestasis type 2 (BRIC 2) (7, 8) and Intrahepatic Cholestasis of Pregnancy (9, 10). Mouse Bsep transports bile acids in the order of preference: taurochenodeoxycholate > tauroursodeoxycholate = taurocholate > glycocholate = cholate (11-16). Rat liver plasma membrane vesicles exhibit similar preference (17). The bile acid preferences and activity of BSEP are similar among human, rat and mouse.

[0006] *bsep* knockout (KO) mice suffer a cholestatic illness with increased mortality in pups, decreased fertility in adults, and bile flow only 1/4 of normal amounts (18). Residual bile flow in *bsep* KO mice is greater than that of PFIC2 patients, and the phenotype less severe, in that *bsep* KO mice can survive infancy and have a normal lifespan (18). The livers of *bsep* KO mice express elevated levels of P-glycoprotein (Mdr1a/1b) and their bile contains novel species of bile acid, including tetrahydroxylated bile acids (THBAs) not normally present in mouse or human bile (16, 18). When fed a diet of 0.5% cholate the *bsep* KO mice become severely cholestatic but at the same time secrete a large amount of bile salt into the bile. To explain this apparently contradictory result, a 'rain barrel' model was proposed, suggesting the containment level of bile salt in hepatocytes depends on both the affinity of the transporter for bile acids (K_m) and the rate of bile acid output (19). The *bsep* KO mice exhibit severe cholestasis on a cholate-enriched diet, since their high bile flow rate and bile acid output is mediated by a transporter whose K_m is not low enough to reduce accumulated intrahepatic bile salt below toxic levels. The rain barrel model predicts that the alternative bile salt transporter has a lower affinity for cholate than BSEP.

[0007] When plasma membrane vesicles from the hamster B30 cell line, containing a high level of P-glycoprotein (Mdr1, Abcb1a) were examined, ATP-dependent taurocholate transport (20) with a K_m of 69 μM, about seven-fold higher than Bsep was observed, suggesting P-glycoprotein transports taurocholate with a relatively low affinity. Analysis of biliary bile salt composition in *bsep* KO mice indicates that P-glycoprotein favours the less hydrophobic muricholates and THBAs over the more hydrophobic primary bile acids in both human and mouse (18, 21). This may explain the differing severity of the cholestatic phenotypes in *bsep* KO mice and PFIC2 in humans. In the *bsep* KO mice, murine P-glycoprotein transports intrahepatic muricholate and THBAs, across the canalicular membranes to maintain nearly normal bile flow, resulting in a mild phenotype. Since humans do not normally synthesize muricholate or THBAs, this option is

not available to human MDR1 and results in the severe cholestasis of PFIC2 where bile flow diminishes to 1% of normal (2).

[0008] Upregulated Mdr1a/1b expression (16, 20) in the *bsep* knockout mice, and the known functional redundancy of the ABCB/P-glycoprotein family suggested a role for Mdr1 in mediating bile flow. However, while the *bsep* knockout mice exhibit very mild cholestasis throughout life, *mdr1a*$^{-/-}$/*mdr1b*$^{-/-}$ double knockout mice are healthy, with no obvious phenotype, though they do have specific defects in biliary excretion of infused drugs that are known to be Mdr1 substrates (22).

[0009] Some cholestatic conditions, such as Primary Biliary Cirrhosis, are treated by supplementation with a low-toxicity bile acid not normally found in human bile, ursodeoxycholate. Dietary supplementation with ursodeoxycholate did not result in greater bile flow in *bsep* KO mice and may even have been toxic, suggesting that BSEP is responsible for the bulk of natural ursodeoxycholate transport, and so ursodeoxycholate may not help PFIC2 patients or anyone else suffering from a BSEP insufficiency, whether inherited, associated with pregnancy, or resulting from adverse drug or dietary exposures.

SUMMARY OF THE INVENTION

[0010] The invention provides, in part, polyhydroxylated bile acids for treating biliary disorders, for example, biliary disorders arising out of cholestasis or portal hypertension, or for stimulating bile flow in for example normal subjects or subjects not diagnosed with a biliary disorder.

[0011] In one aspect, the invention provides a method of treating a bile disorder in a subject in need thereof or of stimulating bile flow in a subject, the method comprising administering an effective amount of a compound according to Formula I:



or a derivative thereof, wherein any one of R_1 to R_9 may be –H or –OH, provided that at least four of R_1 to R_9 are –OH; and R_{10} may be –COOH or $-CH_2OH$.

[0012] In an alternative aspect, the invention provides a pharmaceutical or nutritional composition comprising a compound according to Formula I:



or a derivative thereof, together with a pharmaceutically or physiologically or nutritionally acceptable carrier, wherein any one of R_1 to R_9 may be –H or –OH, provided that at least four of R_1 to R_9 are –OH; and R_{10} may be –COOH or $-CH_2OH$.

[0013] In an alternative aspect, the invention provides the use of a pharmaceutical or nutritional composition according to the invention for the preparation of a medicament for treating a biliary disorder or stimulating bile flow.

[0014] In an alternative aspect, the invention provides an article of manufacture comprising a compound according to Formula I:



or a derivative thereof, together with instructions for use in treating a biliary disorder or stimulating bile flow, wherein any one of R_1 to R_9 may be –H or –OH, provided that at least four of R_1 to R_9 are –OH; and R_{10} may be –COOH or $-CH_2OH$.

[0015] In alternative embodiments, the compound comprises a hydrophilicity greater than that of cholate.

[0016] In alternative embodiments, the compound is selected from the group consisting of a tetrahydroxylated bile acid, a pentahydroxylated bile acid, or a derivative thereof.

[0017] The tetra-hydroxylated bile acid may be a 3,6,7,12-tetrahydroxycholanoic acid, a 3,4,7,12-tetrahydroxycholanoic acid, a 1,3,7,12-tetrahydroxycholanoic acid, a 2,3,7,12-tetrahydroxycholanoic acid, a 3,7,16,24-tetrahydroxycholanoic acid, or a 3,7,15,24-tetrahydroxycholanoic acid, or a derivative thereof.

[0018] The 3,6,7,12-tetrahydroxycholanoic acid may be a 3α, 6α, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid, a 3α, 6β, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid, a 3α, 6α, 7β, 12α-tetrahydroxy-5β-cholan-24-oic acid, a 3α, 6β, 7β, 12α-tetrahydroxy-5β-cholan-24-oic acid, a 3α, 6α, 7α, 12β-tetrahydroxy-5β-cholan-24-oic acid, a 3α, 6β, 7α, 12β-tetrahydroxy-5β-cholan-24-oic acid, or a 3α, 6β, 7β, 12β-tetrahydroxy-5β-cholan-24-oic acid, or a derivative thereof.

[0019] The 3,6,7,12-tetrahydroxycholanoic acid may be a 3β, 6α, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid, a 3β, 6β, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid, a 3β, 6α, 7β, 12α-tetrahydroxy-5β-cholan-24-oic acid, a 3β, 6β, 7β, 12α-tetrahydroxy-5β-cholan-24-oic acid, a 3β, 6α, 7α, 12β-tetrahydroxy-5β-cholan-24-oic acid, a 3β, 6β, 7α, 12β-tetrahydroxy-5β-cholan-24-oic acid, or a 3β, 6β, 7β, 12β-tetrahydroxy-5β-cholan-24-oic acid, or a derivative thereof.

[0020] The 2,3,7,12-tetrahydroxycholanoic acid may be 2α,3α,7α,12α-tetrahydroxy-5β-cholanoic acid, or a derivative thereof.

[0021] The 3,4,7,12-tetrahydroxycholanoic acid may be 3α,4α,7α,12α-tetrahydroxy-5β-cholanoic acid, or a derivative thereof.

[0022] In alternative embodiments, the compound has a preferential affinity for MDR1 when compared to BSEP e.g., the compound has a high affinity for MDR1.

[0023] In alternative embodiments, the compound may be a conjugated compound, e.g., a taurine or a glycine conjugate e.g., tauryl or glycyl conjugate of a 3α, 6β, 7α, 12β-tetrahydroxy-5β-cholan-24-oic acid, a tauryl or glycyl conjugate of a 3α, 6β, 7β, 12β-tetrahydroxy-5β-cholan-24-oic acid, a tauryl conjugate of a 3α, 6β, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid, or tauryl conjugate of a 3α, 6β, 7β, 12α-tetrahydroxy-5β-cholan-24-oic acid.

[0024] In alternative embodiments, the method may comprise administering at least one other therapeutic or prophylactic agent e.g., an agent having preferential affinity for BSEP, or at least one other nutritional supplement. The therapeutic or prophylactic agent or nutritional supplement may be ursodeoxycholate or a variant or derivative thereof.

[0025] In alternative embodiments, the biliary disorder may be benign biliary strictures, benign pancreatic disease cysts, diverticulitis, liver fibrosis, liver damage, common bile duct stones, pancreatitis, pancreatic cancer or pseudocyst, periampullary cancer, bile duct carcinoma, primary sclerosing cholangitis, autoimmune cholangitis, extrinsic duct compression (e.g., compression due to a mass or tumor on a nearby organ), viral hepatitis, sepsis, bacterial abscess, use of drugs e.g., drug-induced idiosyncratic hepatotoxicity, lymphoma, tuberculosis, metastatic carcinoma, sarcoidosis, amyloidosis, intravenous feeding, primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic hepatitis with or without cirrhosis, nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, chronic hepatitis with or without cirrhosis, intrahepatic cholestasis of pregnancy, biliary calculosis, biliary dyscinesia, Sjogren syndrome, Wilson's disease, ischemia, toxins, alcohol, acute liver failure, α1-antitrypsin deficiency, PFIC2, Benign Recurrent Intrahepatic Cholestasis, hepatocellular carcinoma, portal hypertension, veno-occlusive disease, or hepatic vein thrombosis. The biliary disorder may arise or potentially arise from cholestasis.

[0026] In alternative embodiments, the subject may be a human.

[0027] This summary of the invention does not necessarily describe all features of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

[0028] **FIGURE 1** shows the cholestatic phenotype of the triple knockout (mdr1$1^{-/-}$/$mdr1a^{-/-}$/$1b^{-/-}$) mice: a) A view of abdomens showing liver enlargement of a TKO mouse in comparison with b) a wildtype mouse; c) Periportal fibrosis in the livers of a two month old male TKO mouse (Masson trichrome staining), 40x; d) Ultrastructual changes in hepatocytes, showing dilated

canalicular lumen, loss of microvilli (arrows), and retained biliary material in the form of lamellae.

[0029] **FIGURE 2** shows the survival rate (**a**) and body weight changes (**b**) of the "triple knockout" (*bsep*$^{-/-}$/*mdr1a*$^{-/-}$/*1b*$^{-/-}$) mice after being fed 0.5% cholic acid (CA).

[0030] **FIGURE 3** shows the generation of "triple knockout" (*bsep*$^{-/-}$/*mdr1a*$^{-/-}$/*mdr1b*$^{-/-}$) mice: **a)** Crossing scheme for generating TKO mice. The *mdr1a*$^{-/-}$/*mdr1b*$^{-/-}$ double knockout and *bsep*$^{-/-}$ mice were used to generate the triply heterozygotic *bsep*$^{+/-}$/ *mdr1a*$^{+/-}$/*mdr1b*$^{+/-}$ mice (100% of offspring are triple heterozygotes). The triple heterozygotes were used to produce *bsep*$^{+/-}$/*mdr1a*$^{-/-}$/*mdr1b*$^{-/-}$ mice (approximately 1/8 of the offspring since the *mdr1a* and *mdr1b* genes in mice are closely linked), which were then used to generate the TKO homozygotes (*bsep*$^{-/-}$/ *mdr1a* $^{-/-}$/ *mdr1b* $^{-/-}$). **b)** A PCR screening result for the TKO mice. Lanes 1, 5 and 6 are triple knockout mice, in which only bands from mutant alleles were amplified.

[0031] **FIGURE 4** shows the ultrastructual changes in hepatocytes of a TKO (*bsep*$^{-/-}$/*mdr1a*$^{-/-}$/*1b*$^{-/-}$) mouse and an *mdr1a*$^{-/-}$/*1b*$^{-/-}$ control that shows no ultrastructural liver abnormality. ***a)*** On the left, showing abnormal mitochondria of variable size with cristae that are pushed to one side with small ledges not crossing the midline. Their mitochondrial matrix is homogeneous and granules are absent. To the right, this image shows great numbers of hypertrophied Golgi vesicles filled with dense material (arrow). ***b)*** The liver of an *mdr1a*$^{-/-}$/*1b*$^{-/-}$ mouse showing no ultrastructural abnormalities. The arrow points to a normal canaliculus.

[0032] **FIGURE 5** shows the ***a)*** relative mRNA expression of some major liver-expressed genes in wild-type, *bsep*$^{-/-}$ and TKO mice as determined by semi-quantitative real-time PCR. The mRNA levels were normalized against those of ribosomal protein S15. The level of female wild-type mRNA was set at 1. All numbers are expressed as a ratio of female wild-type mRNA, mean ± standard deviation (n = 4) (16). ***b)*** The major alternatively spliced Mdr1 (Abcb1b) transcript in the TKO mice. This transcript has an exon 4 deletion and results in translation of 38 original amino acids followed by a frame shift, 6 novel amino acids and a premature stop codon. ***c)*** The minor Mdr1 (Abcb1b) transcript in TKO mice. This transcript has a deletion of exons 4, 5, and 6 that results in translation of 38 original amino acids followed by a frame shift, 12 novel amino acids and a premature stop codon.

[0033] **FIGURE 6** shows confocal microsopic pictures immunostained for MDR1 or BSEP. MDR1 expression exhibits a strongly canalicular distribution. The lefthand panels are the controls, a liver biopsy from an infant with organic acidemia who did not have jaundice or cholestasis. The right panels are from a liver biopsy sample from a PFIC2 patient.

[0034] **FIGURES 7A-B** show that 3α, 6α, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid stimulates bile flow rate (BFR) in wild-type mice. (A) BFR as a function of body weight in mice after infusion of 3α, 6α, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid (6α, 7α THBA). (B) BFR as a function of body weight in mice after infusion of cholic acid (CA) (3α, 7α, 12α-trihydroxy-5β-cholan-24-oic acid).

[0035] **FIGURE 8 A-B** shows HPLC (High Performance Liquid Chromatography) profiles of bile salt in the bile of a male wild type mouse before **(A)** and after **(B)** infusion of unconjugated 3α, 6α, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid (6α, 7α THBA, 100 μmol/kg as a function of body weight). **(C)** shows HPLC profiles of bile fractions collected from a wild-type mouse before (upper trace), and 2-4 minutes after (lower trace), infusion (100 μmol/kg) of cholic acid (3α, 7α, 12α-trihydroxy-5β-cholan-24-oic acid). The bile samples were collected from a wild type mouse by bile duct cannulation. Equal volumes of bile were loaded.

[0036] **FIGURE 9** shows synthetic steps for production of 3α, 6 α 7α 12α-tetrahydroxy-5β-cholanoic acid (6α, 7α THBA) from cholic acid.

[0037] **FIGURE 10** shows synthetic steps for production of taurine-conjugated 3α, 6 α 7α 12α-tetrahydroxy-5β-cholanoic acid.

[0038] **FIGURE 11** shows 1H-NMR spectrum of taurine-conjugated 3α, 6 α 7α 12α-tetrahydroxy-5β-cholanoic acid (18), produced by the method shown in Figure 10.

[0039] **FIGURE 12 A-C** shows induction of bile flow rate (BFR) by THBA in wild-type mice. **(A)** BFR as a function of body weight (BW) before and after the infusion of 3α, 6β, 7α, 12α-tetrahydroxy-5β – cholan-24-oic acid 3α, 6β, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid (6β, 7α THBA) of 65 (○, open circle), 250 (*star), 350 (▲, solid triangle) and 400 (■, solid square) μmol/kg BW. (**B**). BFR as a function of body weight before and after the infusion of 3α, 6α, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid (6α 7α THBA) of 65 (○, open circle) and 200 (■, solid square) μmol/kg BW. (**C**). BFR as a function of body weight before and after the infusion of 65

μmol/kg body weight of 6β, 7αTHBA (■, solid square), 6α, 7α THBA (▲, solid triangle) and ursodeoxycholic acid (UDC) (○, open circle). Results are represented as the mean ± the standard deviation of three mice. UDC at 65 μmol/kg body weight is the maximum tolerated dose (MTD) in the mice.

DETAILED DESCRIPTION

[0040] The present invention provides, in part, polyhydroxylated bile acids as agents of bile salt therapy to promote or improve biliary secretion in subjects with biliary disorders. Compounds according to the invention can be used in combination with the existing compounds, such as ursodeoxycholate or a variant or derivative thereof, to improve liver function and/or ameliorate a bile disorder. The polyhydroxylated bile acids of the invention are choleretic (possess bile flow-stimulating properties) when administered to a subject e.g., a child awaiting liver transplantation. In alternative embodiments, the invention provides polyhydroxylated bile acids for stimulating bile flow in any subject, for example, a subject not diagnosed with a biliary disorder. By "stimulating bile flow" is meant increasing bile flow in a subject relative to a standard (e.g., standard levels of bile acid in an organism), or relative to the level of bile measured in the subject prior to administration of a polyhydroxylated bile acid according to the invention. The increase may be a change of any integer value between 5% and 95%, or between 10% and 90%, or between 30% and 60%, or may be over 100%. As used herein, a subject may be a human, non-human primate, rat, mouse, cow, horse, pig, sheep, goat, dog, cat, etc. The subject may be a clinical patient, a clinical trial volunteer, an experimental animal, etc. The subject may be suspected of having or at risk for having a biliary disorder, be diagnosed with a biliary disorder, or be subject confirmed to not have a biliary disorder. Diagnostic methods for biliary disorders and methods for measurement of bile flow, as well as the clinical delineation of biliary disorder diagnoses, are known to those of ordinary skill in the art.

[0041] **Biliary disorders**

[0042] Biliary disorders include any disorder or condition that can be ameliorated, treated or prevented by the administration of a polyhydroxylated bile acid. Exemplary biliary disorders may include without limitation bile deficiency, bile toxicity, digestive disorders, impaired liver function, cholestasis, portal hypertension, etc.

[0043] Cholestasis refers to a condition in which the flow of bile from the liver is reduced or blocked, or in which there is a failure in bile flow. Bile flow failures may arise anywhere in the hepatic and biliary system. In general, cholestasis may be extrahepatic cholestasis, which occurs outside the liver cells, or may be intrahepatic cholestasis, which occurs inside the liver cells.

[0044] Extrahepatic cholestasis can result from benign biliary strictures, benign pancreatic disease cysts, diverticulitis, liver damage, common bile duct stones, pancreatitis, pancreatic cancer or pseudocyst, periampullary cancer, bile duct carcinoma primary sclerosing cholangitis, extrinsic duct compression, for example, compression due to a mass or tumor on a nearby organ.

[0045] Intrahepatic cholestasis can be caused by viral hepatitis including but not limited to Hepatitis B and C, sepsis, bacterial abscess, drugs e.g., drug-induced idiosyncratic hepatotoxicity, lymphoma, tuberculosis, metastatic carcinoma, sarcoidosis, amyloidosis, intravenous feeding, primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic hepatitis with or without cirrhosis, chronic hepatitis with or without cirrhosis, pregnancy, Sjogren syndrome, etc. Drug-induced cholestasis is the blockage of the flow of bile from the liver caused by medication, and may be caused by: gold salts, nitrofurantoin, anabolic steroids, oral contraceptives, chlorpromazine, prochlorperazine, sulindac, cimetidine, erythromycin, tobutamide, imipramine, ampicillin and other penicillin-based antibiotics, etc. Drug-induced cholestasis and hepatotoxicity are common obstacles to drug therapy in the clinic and pose major problems for drug development and for novel applications of approved drugs. Drug-induced cholestasis also accounts for 2-5% of patients hospitalized with jaundice, ~10% of all cases of acute hepatitis, and over 50% of acute liver failure.

[0046] Cholestasis may also result from inherited cholestatic liver disease, from drug-induced cholestasis arising from the BSEP-inhibitory activity of certain drugs, and acute hepatotoxic reactions brought about by drugs and inflammatory conditions which impact liver function.

[0047] Portal hypertension refers to a disorder manifesting as increased pressure in the portal vein, which is the vein that conducts blood from the intestine to the liver. The increased pressure in the portal vein may be due to a variety of causes, including inflammation, fibrosis, splenic arteriovenous fistulae, splenic or portal vein thrombosis, massive splenomegaly, sarcoidosis, schistosomiasis, nodular regenerative hyperplasia, primary biliary cirrhosis, hepatitis, autoimmune disease, etc.

[0048] A biliary disorder according to the invention is any disorder arising, or potentially arising, from cholestasis, portal hypertension, or any disorder benefited by the administration of a poly-hydroxylated bile acid as described herein. Biliary disorders include without limitation benign biliary strictures, benign pancreatic disease cysts, diverticulitis, liver fibrosis, liver damage, common bile duct stones, pancreatitis, pancreatic cancer or pseudocyst, periampullary cancer, bile duct carcinoma, primary sclerosing cholangitis, autoimmune cholangitis, extrinsic duct compression (e.g., compression due to a mass or tumor on a nearby organ, viral hepatitis (e.g., Hepatitis A, B, C, D, E, herpes simplex, cytomegalovirus, Epstein-Barr, adenovirus), sepsis, bacterial abscess, use of drugs e.g., drug-induced idiosyncratic hepatotoxicity, lymphoma, tuberculosis, metastatic carcinoma, sarcoidosis, amyloidosis, intravenous feeding, primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic hepatitis with or without cirrhosis, nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, chronic hepatitis with or without cirrhosis, intrahepatic cholestasis of pregnancy, biliary calculosis, biliary dyscinesia, Sjogren syndrome, Wilson's disease, ischemia, toxins, alcohol, acute liver failure, α1-antitrypsin deficiency, PFIC2, Benign Recurrent Intrahepatic Cholestasis (BRIC), hepatocellular carcinoma (HCC), portal hypertension, veno-occlusive disease, hepatic vein thrombosis, etc.

[0049] **Polyhydroxylated Bile Acids and Derivatives Thereof**

[0050] Bile acids are amphipathic compounds derived from cholesterol and are a subclass of steroids. Bile acids and bile alcohols are steroids whose structure is related to cholane or cholestane; accordingly bile acids and bile alcohols may be termed cholanoids (51). The term "bile acid" is a generic term for cholanoid molecules having a carboxyl group and does not denote an ionization state.

[0051] The term "bile salt" may be used for a salt in which the anion is a conjugated bile acid, an unconjugated bile acid, or a conjugate of a bile alcohol, or may be used as a generic term to include both conjugated bile acids and bile alcohol conjugates occurring in nature as water-soluble anions (51). For example, bile salts may be bile acids conjugated with glycine or taurine as sodium salts.

[0052] The numbering system for the carbon atoms of the bile acid skeleton, as used herein, is as follows.



[0053] C_{24} bile acids are termed cholanoic acids or cholanoates, while C_{27} bile acids are termed cholestanic acids or cholestanoates. In general, the configuration of the side chain is 17β, with a 5β hydrogen (A/B ring junction in *cis* configuration). "Allo" bile acids are bile acids with a 5α hydrogen (51).

[0054] Bile acids may be polyhydroxylated. A polyhydroxylated bile acid compound according to the invention includes without limitation tetrahydroxylated bile acids, pentahydroxylated bile acids, hexahydroxylated bile acids, etc., up to the maximum level of hydroxylation possible.

[0055] In some embodiments, a polyhydroxylated bile acid may be a compound as represented in Formula I:



or a derivative thereof, in which any one of R_1 to R_9 may be –H or –OH, provided that at least four of R_1 to R_9 are –OH; and R_{10} may be –COOH or $-CH_2OH$.

[0056] In some embodiments, any one of R_1 to R_9 may be –H, -OH, -F, -Cl, -Br, alkyl (for example, $-CH_3$, $-CH_2-CH_3$), $-SO_4$, or glucose provided that at least four of R_1 to R_9 are –OH; and R_{10} may be –COOH or $-CH_2OH$.

[0057] In some embodiments, bile acids according to the invention are at least tetrahydroxylated i.e. have four or greater than four hydroxyl groups. In some embodiments, the hydroxyl groups are present on the steroid nucleus. In some embodiments, the hydroxyl groups may also be present on the alkyl side chain.

[0058] A tetrahydroxylated bile acid according to the invention includes, without limitation, a 3,6,7,12-tetrahydroxycholanoic acid; a 3,4,7,12-tetrahydroxycholanoic acid; a 1,2,7,12-tetrahydroxycholanoic acid; a 1,3,7,12-tetrahydroxycholanoic acid; a 2,3,7,12-tetrahydroxycholanoic acid; a 3,7,16,24-tetrahydroxycholanoic acid; or a 3,7,15,24-tetrahydroxycholanoic acid, or derivatives thereof.

[0059] A 3,6,7,12-tetrahydroxycholanoic acid according to the invention includes, without limitation, a 3α, 6α, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid; a 3α, 6β, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid; a 3α, 6α, 7β, 12α-tetrahydroxy-5β-cholan-24-oic acid; a 3α, 6β, 7β, 12α-tetrahydroxy-5β-cholan-24-oic acid; a 3α, 6α, 7α, 12β-tetrahydroxy-5β-cholan-24-

oic acid; a 3α, 6β, 7α, 12β-tetrahydroxy-5β-cholan-24-oic acid, or a 3α, 6β, 7β, 12β-tetrahydroxy-5β-cholan-24-oic acid, or derivatives thereof.

[0060] A 3,4,7,12-tetrahydroxycholanoic acid according to the invention includes, without limitation, a 3α, 4β, 7α, 12α tetrahydroxy-5β-cholan-24-oic acid, a 3α, 4α, 7α, 12α-tetrahydroxy-5β-cholanoic acid, or derivatives thereof.

[0061] A 1,3,7,12-tetrahydroxycholanoic acid according to the invention includes, without limitation, a 1β, 3α, 7α, 12α tetrahydroxy-5β-cholan-24-oic acid, or derivatives thereof.

[0062] A 2,3,7,12-tetrahydroxycholanoic acid according to the invention includes, without limitation, a 2β, 3α, 7α, 12α tetrahydroxy-5β-cholan-24-oic acid, a 2α, 3α, 7α, 12α-tetrahydroxy-5β-cholanoic acid, or derivatives thereof.

[0063] A 3,7,16,24-tetrahydroxycholanoic acid according to the invention includes, without limitation, a 3α, 7α, 16α, 24 tetrahydroxy-5β-cholane or derivatives thereof.

[0064] A 3,7,15,24-tetrahydroxycholanoic acid, according to the invention includes without limitation, a 3α, 7β, 15α, 24 tetrahydroxy-5β-cholane or derivatives thereof.

[0065] In alternative embodiments, polyhydroxylated bile acid compounds according to the invention include, without limitation, a 3α, 7α, 12α, 24 tetrahydroxy-5β–26-oic acid; a 3α, 7α, 12α, 24 tetrahydroxy-5β–Cholest-25-ene; a 3α, 7α, 24, 26 tetrahydroxy-5β– Cholestane; or a 3α, 7α, 12α, 24, 26 pentahydroxy-5β– Cholestane or derivatives thereof.

[0066] In alternative embodiments, polyhydroxylated bile acid compounds according to the invention specifically exclude beta-muricholate and trihydroxy bile acids. In alternative embodiments, polyhydroxylated bile acid compounds according to the invention are more hydrophilic than cholate (23, 24), as measured for example by the distribution and configurations of polar [OH^-] and apolar (H^+) residues along the steroid ring, or by retention times in reverse-phase HPLC (60). In some embodiments, polyhydroxylated bile acid compounds according to the invention have a hydrophobicity of less than 0.45, 0.40, 0.35, 0.30, 0.25, 0.20, 0.15, 0.10, or 0.05 relative to taurocholate (which is assigned a value of 1.0; see for example Asamoto et al. (21)).

[0067] In some embodiments, polyhydroxylated bile acid compounds according to the invention have a preferential affinity for MDR1 when compared to BSEP. In some embodiments, polyhydroxylated bile acid compounds according to the invention have a high affinity to MDR1, e.g., a Km lower than 10 μM, 20 μM, 30 μM, 40 μM, 50 μM, 60 μM, 70 μM, 80 μM, 90 μM, 100 μM or more.

[0068] The term "conjugated bile acid" may be used to indicate a bile acid conjugated to a group that gives additional hydrophilicity or charge to the molecule. In alternative embodiments, the polyhydroxylated bile acid compounds according to the invention include taurine and/or glycine conjugates. In alternative embodiments, the polyhydroxylated bile acid compounds according to the invention include conjugates with any other suitable amino acids. In alternative embodiments, the polyhydroxylated bile acid compounds according to the invention include conjugates with sulfate, phosphate, Coenzyme A, glucuronate, glucose, xylose, and other sugars, N-acetylglucosamine, etc. For example, conjugated polyhydroxylated compounds according to the invention include, without limitation, tauryl or glycyl conjugates of 3α, 6β, 7α, 12β-tetrahydroxy-5β-cholan-24-oic acids, tauryl or glycyl conjugates of 3α, 6β, 7β, 12β-tetrahydroxy-5β-cholan-24-oic acids, tauryl conjugates of 3α, 6β, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acids, tauryl conjugates of 3α, 6β, 7β, 12α-tetrahydroxy-5β-cholan-24-oic acids, ethanesulfonic acid, 2-[(3,6,7,12-tetrahydroxy-24-oxocholan-24- yl)amino], e.g., ethanesulfonic acid, 2-[[(3α,5β,6α,7α,12α)-3,6,7,12-tetrahydroxy-24-oxocholan-24-yl]amino]-,Glycine, N-(3,6,7,12-tetrahydroxy-24-oxocholan-24-yl) e.g., Glycine, N-[(3α,5β,6β,7β,12α)-3,6,7,12-tetrahydroxy-24-oxocholan-24-yl], Glycine, N-[(3α,5β,6β,7α,12α)-3,6,7,12-tetrahydroxy-24-oxocholan-24-yl], Glycine, N-[(3α,5β,6α,7β,12α)-3,6,7,12-tetrahydroxy-24-oxocholan-24-yl], Glycine, N-[(3α,5β,6α,7α,12α)-3,6,7,12-tetrahydroxy-24-oxocholan-24-yl], etc.

[0069] The polyhydroxylated bile acid compounds according to the invention include isomers e.g., stereoisomers. For example, 3β and 5α hydroxy tetrahydroxycholanoic acid are included, as are any stereoisomeric configurations and combinations thereof.

[0070] The polyhydroxylated bile acid compounds according to the invention include physiologically or pharmaceutically-acceptable derivatives, such as salts, esters, enol ethers, enol esters, solvates, hydrates and prodrugs of the compounds described herein. Pharmaceutically-acceptable salts, include, but are not limited to, amine salts, such as but not limited to N,N'-dibenzylethylenediamine, chloroprocaine, choline, ammonia, diethanolamine and other

hydroxyalkylamines, ethylenediamine, N-methylglucamine, procaine, N-benzylphenethylamine, 1-para-chlorobenzyl-2-pyrrolidin-1'-ylmethylbenzimidazole, diethylamine and other alkylamines, piperazine and tris(hydroxymethyl)aminomethane; alkali metal salts, such as but not limited to lithium, potassium and sodium; alkali earth metal salts, such as but not limited to barium, calcium and magnesium; transition metal salts, such as but not limited to zinc, aluminum, and other metal salts, such as but not limited to sodium hydrogen phosphate and disodium phosphate; and also including, but not limited to, salts of mineral acids, such as but not limited to hydrochlorides and sulfates; and salts of organic acids, such as but not limited to acetates, lactates, malates, tartrates, citrates, ascorbates, succinates, butyrates, valerates and fumarates.

[0071] Compounds and salts thereof of this invention and for use in this invention are generally provided in substantially purified form. A compound or salt (if naturally occurring) is "substantially pure" or "isolated" when it is separated from the components that naturally accompany it (e. g, cells of a source organism or tissue). A compound may be substantially pure or isolated when it is substantially free of cellular contaminants, i. e, that it is present ex vivo and in a concentration greater than that of the compound in a source organism, tissue, or other natural source. Typically, a compound is substantially pure or isolated when it is at least 10%, 20%, 30%, 40%, 50%, or 60%, more generally 70%, 75%, 80%, or 85%, or over 90%, 95%, or 99% by weight, of the total material in a sample. Thus, for example, a compound that is chemically synthesized will generally be substantially free from its naturally associated components. A substantially pure compound can be obtained, for example, by extraction from a natural source or by chemical synthesis. A substantially pure compound may include stereoisomers or differentially hydroxylated mixtures. Purity can be measured using any appropriate method such as column, gas, or liquid chromatography or mass spectrometry.

[0072] In an alternative embodiment of the invention, a composition comprising a racemic mixture of a tetrahydroxylated bile acid is provided. The racemic mixture may be produced as a result of the chemical synthesis of the tetrahydroxylated bile acid; alternatively, two or more stereochemically pure enantiomers may be combined. In another embodiment, the composition may comprise two or more tetrahydroxylated bile acids.

[0073] **Preparation of Polyhydroxylated Bile Acids**

[0074] Compounds according to the invention, or for use according to the invention, including pharmaceutically acceptable salts or derivatives thereof, may be obtained by synthesis making use of common procedures as exemplified herein or known in the art. Some compounds that may be used according to the invention can be obtained from natural sources. For example, polyhydroxylated bile acid compounds may be prepared in part or in whole from natural sources, e. g. , by fractionating biological extracts (e.g , from *bsep* KO mice). Bile acids may be obtained from *bsep* KO mice by for example using bile duct cannulation to collect about 10-20 ml bile from 50-100 *bsep* KO mice. HPLC may be used to isolate about 10-20 μmol (5-10 mg) tetra-hydroxylated bile acid. In some embodiments, polyhydroxylated bile acid compounds according to the invention may be prepared by total synthesis. Such synthetic compounds can, optionally, be labeled or derivatized for analytical or drug development purposes.

[0075] The compounds may be synthesized using standard techniques such as those described in Tohma et al., 1985 (52); Iida et al, 1991a (53); Iida et al., 1991b (54); Aggarwal et al., 1992 (55); Iida et al., 1993 (56); Kurosawa et al, 1995 (57); Kurosawa et al., 1996 (58); Iida et al, 2002 (59); Tserng KY and Klein PD (1977), Leppik RA (1983), or Iida T. et al. (1990) etc., all of which are specifically incorporated by reference. For example, tetrahydroxy bile acids may be prepared as indicated in Tohma et al., 1985 (52); Iida et al., 1991b (54); Aggarwal et al., 1992 (55); Iida et al., 1993 (56); Kurosawa et al., 1996 (58); Iida et al, 2002 (59); pentahydroxy bile acids may be prepared as indicated in Kurosawa et al., 1996 (58).

[0076] **Pharmaceutical or Nutritional Supplement Compositions, Dosages, and Administration of Poly-Hydroxylated Bile Acids**

[0077] The polyhydroxylated bile acid compounds of the invention can be provided alone or in combination with other compounds (for example, nucleic acid molecules, small molecules, peptides, or peptide analogues), in the presence of a liposome, an adjuvant, or any pharmaceutically or physiologically acceptable carrier, in a form suitable for administration to humans or animals. If desired, treatment with a compound according to the invention may be combined with more traditional and existing therapies for biliary disorders or disorders resulting in or potentially resulting in hepatotoxicity, or with existing nutritional supplements for stimulating bile flow. In some embodiments, polyhydroxylated bile acids according to the invention are administered to subjects not diagnosed with a biliary disorder (e.g., a normal

subject) to stimulate bile flow. In some embodiments, polyhydroxylated bile acids according to the invention are administered under conditions where BSEP is inhibited and where the approved therapeutic agent for cholestasis, ursodeoxycholate, is ineffective. In some embodiments, polyhydroxylated bile acids according to the invention are administered together with ursodeoxycholate or a variant or derivative thereof (e.g., sulfated ursodeoxycholate, nitrodeoxycholate, taurodeoxycholate, etc.), Rifampicin, or any compound useful for treating cholestasis or portal hypertension or for stimulating bile flow.

[0078] Conventional pharmaceutical or nutritional supplement formulation practice may be employed to provide suitable formulations or compositions to administer the compounds to patients suffering from or presymptomatic for cholestasis, or to normal subjects for stimulating bile flow. Any appropriate route of administration may be employed, for example, parenteral, intravenous, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intracistemal, intraperitoneal, intranasal, aerosol, or oral administration. Therapeutic formulations may be in the form of liquid solutions or suspensions; for oral administration, formulations may be in the form of tablets or capsules; and for intranasal formulations, in the form of powders, nasal drops, or aerosols.

[0079] Methods well known in the art for making formulations are found in, for example, "Remington's Pharmaceutical Sciences" (19th edition), ed. A. Gennaro, 1995, Mack Publishing Company, Easton, Pa. Formulations for parenteral administration may, for example, contain excipients, sterile water, or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated napthalenes. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds. Other potentially useful parenteral delivery systems for modulatory compounds include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation may contain excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel.

[0080] For therapeutic or prophylactic compositions, the compounds are administered to a subject in an amount sufficient to stop or slow cholestasis or to maintain or increase bile flow or

to ameliorate portal hypertension. For nutritional supplements, the compounds are administered to a subject in an amount sufficient to stimulate bile flow.

[0081] As discussed herein, a significant upregulation of MDR1 expression was found in livers of PFIC patients, indicating that MDR1 can be targeted in drug therapy for cholestatic diseases such as PFIC2 and other biliary disorders indicated herein. BSEP and MDR1 are loci of significant polymorphism in human populations, and some BSEP variants are associated with susceptibility to liver diseases. For example, the V444A polymorphism in BSEP is present in about half the population and is associated with a ~60% increased risk of intrahepatic cholestasis of pregnancy. Other forms of biliary disorders manifesting elevated MDR1 expression can also be treated using the compounds according to the invention. Compounds according to the invention can also provide therapeutic benefit to patients suffering from inherited cholestatic liver disease, from drug-induced cholestasis arising from the BSEP-inhibitory activity of certain drugs, or from other biliary disorders, and can help alleviate acute hepatotoxic reactions brought about by drugs and inflammatory conditions which impact biliary function.

[0082] An "effective amount" of a compound according to the invention includes a therapeutically effective amount or a prophylactically effective amount or a nutritionally effective amount. A "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, such as increased bile flow, relief of jaundice, or improved liver functions as indicated by normalization of serum liver biochemical indicators, such as the levels of bilirubins, ALP (alkaline phosphatase), ALT (alanine aminotransferase), AST (aspartate aminotransferase) , γ-GT (Gamma-Glutamyl Transpeptidase), etc. A therapeutically effective amount of a compound may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the compound to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. A therapeutically effective amount is also one in which any toxic or detrimental effects of the compound are outweighed by the therapeutically beneficial effects. A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result, such as increased bile flow or improved liver functions as indicated by liver biochemical indicators, increased bile flow, relief of jaundice, or improved liver functions as indicated by normalization of serum liver biochemical indicators, such as the levels of bilirubins, ALP (alkaline phosphatase), ALT (alanine aminotransferase), AST (aspartate aminotransferase), γ-GT (Gamma-Glutamyl

Transpeptidase), etc. Typically, a prophylactic dose is used in subjects prior to or at an earlier stage of disease, so that a prophylactically effective amount may be less than a therapeutically effective amount. An exemplary range for therapeutically or prophylactically effective amounts of a compound may be 5-50 mg/day/kg of body weight of the subject e.g., a human. A "nutritionally effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired result, such as increased bile flow or improved liver functions as indicated by liver biochemical indicators.

[0083] It is to be noted that dosage values may vary with the severity of the condition to be alleviated. For any particular subject, specific dosage regimens may be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions. Dosage ranges set forth herein are exemplary only and do not limit the dosage ranges that may be selected by medical practitioners. The amount of active compound in the composition may vary according to factors such as the disease state, age, sex, and weight of the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It may be advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage.

[0084] In the case of vaccine formulations, an immunogenically effective amount of a compound of the invention can be provided, alone or in combination with other compounds, with an adjuvant, for example, Freund's incomplete adjuvant or aluminum hydroxide. The compound may also be linked with a carrier molecule, such as bovine serum albumin or keyhole limpet hemocyanin to enhance immunogenicity.

[0085] For nutritional supplements, at least one additive, including one listed below, can be included for consumption with the nutritional supplement of the invention and may have, for example, antioxidant, dispersant, antimicrobial, or solubilizing properties. A suitable antioxidant is, for example, vitamin C, vitamin E or rosemary extract. A suitable dispersant is, for example, lecithin, an alkyl polyglycoside, polysorbate 80 or sodium lauryl sulfate. A suitable antimicrobial is, for example, sodium sulfite or sodium benzoate. A suitable solubilizing agent is, for example, a vegetable oil such as sunflower oil, coconut oil, and the like, or mono-, di- or tri-glycerides. Additives include vitamins such as vitamin A (retinol, retinyl palmitate or retinol acetate),

vitamin B1 (thiamin, thiamin hydrochloride or thiamin mononitrate), vitamin B2 (riboflavin), vitamin B3 (niacin, nicotinic acid or niacinamide), vitamin B5 (pantothenic acid, calcium pantothenate, d-panthenol or d-calcium pantothenate), vitamin B6 (pyridoxine, pyridoxal, pyridoxamine or pyridoxine hydrochloride), vitamin B12 (cobalamin or cyanocobalamin), folic acid, folate, folacin, vitamin H (biotin), vitamin C (ascorbic acid, sodium ascorbate, calcium ascorbate or ascorbyl palmitate), vitamin D (cholecalciferol, calciferol or ergocalciferol), vitamin E (d-alpha-tocopherol, d-beta-tocopherol, d-gamma-tocopherol, d-delta-tocopherol or d-alpha-tocopheryl acetate) and vitamin K (phylloquinone or phytonadione). Other additives include minerals such as boron (sodium tetraborate decahydrate), calcium (calcium carbonate, calcium caseinate, calcium citrate, calcium gluconate, calcium lactate, calcium phosphate, dibasic calcium phosphate or tribasic calcium phosphate), chromium (GTF chromium from yeast, chromium acetate, chromium chloride, chromium trichloride and chromium picolinate) copper (copper gluconate or copper sulfate), fluorine (fluoride and calcium fluoride), iodine (potassium iodide), iron (ferrous fumarate, ferrous gluconate or ferrous sulfate), magnesium (magnesium carbonate, magnesium gluconate, magnesium hydroxide or magnesium oxide), manganese (manganese gluconate and manganese sulfate), molybdenum (sodium molybdate), phosphorus (dibasic calcium phosphate, sodium phosphate), potassium (potassium aspartate, potassium citrate, potassium chloride or potassium gluconate), selenium (sodium selenite or selenium from yeast), silicon (sodium metasilicate), sodium (sodium chloride), strontium, vanadium (vanadium sulfate) and zinc (zinc acetate, zinc citrate, zinc gluconate or zinc sulfate). Other additives include amino acids, peptides, and related molecules such as alanine, arginine, asparagine, aspartic acid, carnitine, citrulline, cysteine, cystine, dimethylglycine, gamma-aminobutyric acid, glutamic acid, glutamine, glutathione, glycine, histidine, isoleucine, leucine, lysine, methionine, ornithine, phenylalanine, proline, serine, taurine, threonine, tryptophan, tyrosine and valine. Other additives include animal extracts such as cod liver oil, marine lipids, shark cartilage, oyster shell, bee pollen and d-glucosamine sulfate. Other additives include unsaturated free fatty acids such as linoleic, arachidonic and linolenic acid, which may be in an ester (e.g. ethyl ester or triglyceride) form. Other additives include herbs and plant extracts such as kelp, pectin, Spirulina, fiber, lecithin, wheat germ oil, safflower seed oil, flax seed, evening primrose, borage oil, blackcurrant, pumpkin seed oil, grape extract, grape seed extract, bark extract, pine bark extract, French maritime pine bark extract, muira puama extract, fennel seed extract, dong quai extract, chaste tree berry extract, alfalfa, saw palmetto berry extract, green tea extracts, angelica, catnip, cayenne, comfrey, garlic, ginger, ginseng, goldenseal, juniper berries, licorice, olive oil,

parsley, peppermint, rosemary extract, valerian, white willow, yellow dock and yerba mate. Other additives include enzymes such as amylase, protease, lipase and papain as well as miscellaneous substances such as menaquinone, choline (choline bitartrate), inositol, carotenoids (beta-carotene, alpha-carotene, zeaxanthin, cryptoxanthin or lutein), para-aminobenzoic acid, betaine HCl, free omega-3 fatty acids and their esters, thiotic acid (alpha-lipoic acid), 1,2-dithiolane-3-pentanoic acid, 1,2-dithiolane-3-valeric acid, alkyl polyglycosides, polysorbate 80, sodium lauryl sulfate, flavanoids, flavanones, flavones, flavonols, isoflavones, proanthocyanidins, oligomeric proanthocyanidins, vitamin A aldehyde, a mixture of the components of vitamin A_2, the D Vitamins (D_1, D_2, D_3 and D_4) which can be treated as a mixture, ascorbyl palmitate and vitamin K_2. The nutritional supplement of the invention is typically a viscous oil and can be added to a foodstuff composition during processing of the foodstuff. Such a foodstuff composition is often referred to as a functional food, and can be any food that will tolerate the physicochemical properties of the nutritional supplement, for example, margarine, cooking oil, shortening or mayonnaise. It can also be packaged for consumption in softgel, capsule, tablet or liquid form. It can be supplied in edible polysaccharide gums, for example carrageenan, locust bean gum, guar, tragacanth, cellulose and carboxymethylcellulose.

[0086] In general, compounds of the invention should be used without causing substantial toxicity. Toxicity of the compounds of the invention can be determined using standard techniques, for example, by testing in cell cultures or experimental animals and determining the therapeutic index, i.e., the ratio between the LD50 (the dose lethal to 50% of the population) and the LD100 (the dose lethal to 100% of the population). Other methods that may be used to determine toxicity of the compounds of the invention include, but are not limited to, histological abnormality by H&E staining, trichrome staining or the like; changes in bile flow rate, and/or clearance of other bile substances (for example, as determined by bile duct cannulation); HPLC analysis, enzymatic assays or the like; changes in liver indicator profiles, for example level of bilirubins, level of ALP (alkaline phosphatase), level of ALT (alanine aminotransferase), level of AST (aspartate aminotransferase), level of γ-GT (Gamma-Glutamyl Transpeptidase), or the like. The maximum tolerated dose (MTD) is the highest regularly administered dose of a compound or composition that does not cause overt toxicity (e.g. does not cause unacceptable side effects) in a subject study over a period of time. The subject may be a human, or an animal, such as a mouse or a rat, for example. The regularly administered dose may be a daily dose, administered as a single bolus; alternately the daily dose may be divided into two or more partial doses so that the

subject receives the total daily dose over time. The period of time of the study may vary from a few days to a few months, for example 10, 20, 30, 60, 90 or 120 days, or any amount therebetween. Examples of overt toxicity may include, but are not limited to, appreciable death of cells or organ dysfunction, toxic manifestations that are predicted materially to reduce the life span of the subject, or 10% or greater retardation of body weight gain.

[0087] In some circumstances however, such as in severe disease conditions, it may be necessary to administer substantial excesses of the compositions. In some embodiments, 3α, 6α, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid or 3α, 6β, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid may have lower toxicity than other bile acids, for example ursodexoxycholate. When used as a nutritional supplement, the appropriate dose should not result in significant toxicity.

[0088] **Articles of manufacture**

[0089] Articles of manufacture containing packaging material, a polyhydroxylated bile acid compound or composition, or pharmaceutically or physiologically acceptable derivative thereof, provided herein, which is effective for stimulating bile flow or for modulating the activity of MDR1, or for treatment, prevention or amelioration of one or more symptoms of cholestasis or biliary disorders in which MDR1 is implicated, within the packaging material, and a label that indicates that the compound or composition, or pharmaceutically acceptable derivative thereof, is used for stimulating bile flow or for modulating the activity of MDR1, or for treatment, prevention or amelioration of one or more symptoms of cholestasis or biliary disorders in which MDR1 is implicated, are provided.

[0090] **Kits**

[0091] A kit comprising a polyhydroxylated bile acid compound, or composition comprising a polyhydroxylated bile acid compound, or pharmaceutically or physiologically acceptable derivatives thereof, provided herein, which is effective for stimulating bile flow or for modulating the activity of MDR1, or for treatment, prevention or amelioration of one or more symptoms of cholestasis or biliary disorders in which MDR1 is implicated, along with instructions for use of the compound or composition, is provided. The kit may be useful for treating a biliary disorder in a subject, and the instructions may include, for example, dose concentrations, dose intervals, preferred administration methods or the like.

[0092] In another embodiment, the kit may be useful for the preparation of a medicament, and the instructions may comprise instructions for the preparation of the medicament. The kit may further comprise instructions for use of the medicament in treatment for treatment, prevention or amelioration of one or more symptoms of cholestasis or biliary disorders in which MDR1 is implicated, and include, for example, dose concentrations, dose intervals, preferred administration methods or the like.

[0093] In another embodiment, the kit may be useful for the preparation of a pharmaceutical or nutritional composition, and the instructions may comprise instructions for the preparation of the pharmaceutical or nutritional composition. The kit may further comprise instructions for use of the pharmaceutical or nutritional composition for treatment, prevention or amelioration of one or more symptoms of cholestasis or biliary disorders in which MDR1 is implicated, and include, for example, dose concentrations, dose intervals, preferred administration methods or the like.

[0094] The present invention will be further illustrated in the following examples.

[0095] **EXAMPLE 1: Animal Model for Cholestasis**

[0096] **Methods**

[0097] Animals

[0098] As described previously, the *bsep* KO mice on an FVB/NJ genetic background (16) were maintained in this laboratory and *mdr1a/1b* KO mice (22) were from Taconic (Hudson, NY 12534). Mice were maintained in a 12-hour light and dark cycle, at 22°C, with free access to food and water. The mice were fed a normal diet except where specified otherwise in the results. Experiments were performed using approved protocols of the Committee on Animal Care, University of British Columbia, according to the guidelines of the Canadian Council on Animal Care.

[0099] Light and transmission electron microscopy

[00100] For light microscopy, mice were killed with CO_2 after 2-4 hours of fasting. Livers were immediately removed and transferred into 10% neutral buffered formalin followed by paraffin sectioning and hematoxylin-eosin staining or Masson trichrome staining (Wax-it Histology Services Inc, Vancouver). For transmission electron microscopy, livers were perfusion-fixed *in-situ* using ice-cold 2.5% glutaraldehyde and kept in 2.5% glutaraldehyde.

Dehydration, plastic-embedding and sectioning were performed as described previously (25). One micron-thick plastic-embedded sections were also obtained and examined in a Philips EM400T transmission electron microscope (Eindhoven, The Netherlands).

[00101] Human Liver Samples

[00102] Five needle biopsy or surgical biopsy liver samples from genetically confirmed PFIC type 1 and 2 patients[1] aged 5 months to 1.5 years of age were obtained. Two PFIC-2 patients were sibling pairs with a heterozygous V284L mutation and a 1bp deletion at nucleotide position 1273. The other PFIC-2 patient had a G1004D missense mutation. Three PFIC-3 patients were included by virtue of having high γ-GT PFIC, including one confirmed deletion mutation in the MDR3 gene (73). Another 6 age-matched controls (0.5 to 1.5 years) from non-jaundiced, non-cholestatic metabolic liver disease or hepatitis patients. Samples were collected under informed consent.

[00103] Quantitative Reverse-Transcription PCR

[00104] Liver samples from mice and patients were used to prepare RNA as previously described (16). Briefly, total RNAs were extracted from frozen liver by the RNAeasy kit (Qiagen GmbH, Hilden, Germany). 1-10 μg of total RNA was reverse-transcribed with 200 pmol of random hexamer (Promega Corp., Madison, WI) and reverse transcriptase (SuperScript II, Invitrogen Life Technologies, Breda, Netherlands) at 42°C for 50 min and inactivated at 72°C for 15min. With the complementary DNA (cDNA) obtained, for mouse samples, PCR reactions were done with the SYBR Green PCRMaster Mix (Foster City, CA) in a PRISM 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA), using the "Standard Curve Method"(ABI PRISM User Bulletin 2). Primers used were as reported previously (16). For each sample, aliquots (5-10 ng) of total RNA were used for each RT-PCR reaction, and the results were normalized against the expression level of ribosomal protein S15 (Rps15). For patient samples, PCR reactions were performed using the Taqman system. Aliquots (5 ng) of total RNA were used for each RT-PCR reaction. The expression levels of MDR relative to TATA box-binding protein (TBP) were calculated using the dCT method (ABI PRISM User Bulletin 2). The primers and probes used were: MDR (Hs00184500_m1, ABI) and *TBP* (sense: 5'-CACGAACCACGGCACTGTT -3' (SEQ ID NO: 1); antisense: 5'-TTTTCTTGCTGCCAGTCTGGAC-3' (SEQ ID NO: 2); probe 5'-JOE TGTGCACAGGAGCCAAGAGTGAAGA-3' (SEQ ID NO: 3)).

[00105] Immunofluorescent Staining

[00106] Samples of fresh liver tissue were embedded in O.C.T. compound (Tissue-Tek; SAKURA) immediately. Frozen tissue sections (~5-7 μm) were cut with a cryostat and placed on poly-L-lysine-coated glass slides, then fixed in cooled acetone for 10 minutes. A rabbit polyclonal antibody against human BSEP (1:500) was used as previously reported (26). Monoclonal antibodies against human MDR with 1:500 dilution (Sigma, Saint Louis Missouri) were used. After rinsing with PBS, the tissue sections were incubated with fluorescent-conjugated secondary antibody to either rabbit or mouse IgG (Alexa Fluor 594 and Alexa Fluor 488, Life Technologies) for 1 hour at room temperature, followed by PBS washing. The sections were mounted with VectaShield (Life Technologies). Images were obtained using a Nikon C1 confocal microscope and processed using Photoimpact 8.0 software (Ulead).

[00107] **Results**

[00108] Triple knockout (TKO) mice carrying null mutations of *mdr1a* and *mdr1b* (co-orthologs of human MDR1) and *bsep* genes by multi-step crossing of *bsep*$^{-/-}$ mice (18) with *mdr1a*$^{-/-}$/*mdr1b* $^{-/-}$ double knockout mice (22) were generated Figure 3a). Null expression of the three mutant genes in the TKO mice was confirmed by genomic PCR (Figure 3b), real time RT-PCR (Figure 5), and Western blotting.

[00109] The TKO mice displayed more severe cholestasis than either parental strain, manifesting as severe jaundice e.g., on the body wall and paws, throughout life, liver enlargement (Figure 1a), disrupted canaliculi (Figure 1d), blocked bile ducts, growth retardation and very high mortality. Under close care, some TKO mice, mostly females, do live to adulthood while about 80% of the TKO males suffer sudden death within 2-6 months. The male adults are fertile and can be used for producing TKO offspring. We further demonstrated that the TKO mice have a reduced tolerance for cholestatic stress by feeding female TKO mice a 0.5% cholic acid diet, a condition that can be well-tolerated by *bsep*$^{-/-}$ females and *mdr1a*$^{-/-}$/*1b*$^{-/-}$ double KO mice. The female TKO mice under a 0.5% CA diet became terminally ill or died after 3-7 days of feeding (Figure 2). This is in sharp contrast with the *bsep*$^{-/-}$ mice, the females of which could sustain 105 days of the same feeding conditions without showing any terminal illness (16).

[00110] The histological presentation of the TKO mice also indicates a much more severe cholestasis in TKO mice than in *bsep*$^{-/-}$ mice. Under a microscope, the hepatocytes of TKO mice

show readily visible periportal fibrosis (Figure 1c) and paucity of bile ducts (17 bile ducts per 91 portal veins in TKO mice *vs.* 68 per 165 counted in wild-type mice). Using electron microscopy, profound hepatic damage was further observed in both plasma membrane and cytoplasm (Figure 1d). The TKO mice exhibited more severe defects as manifested by severely impaired canalicului that have lost almost all microvilli, and dilated canalicular spaces filled with dense bile substances. The hepatocytes of TKO mice also display cytoplasmic abnormalities typical of hepatic toxicity with distorted mitochondria, hypertrophied Golgi apparatus, increased smooth endoplasmic reticulum, excessive lipid droplets, and increased numbers of peroxisomes (Figure 4).

[00111] To determine whether or not Mdr1 is also a physiologically relevant canalicular bile salt transporter that helps to alleviate an otherwise more severe cholestatic phenotype, we selectively blocked Mdr1 (P-glycoprotein) with the P-glycoprotein blocker Cyclosporine A (CsA) in *bsep*$^{-/-}$ mice, in which the major canalicular bile salt transporter Bsep is inactivated. Peritoneal injection of 25mg/kg/day CsA induced a more severe cholestatic phenotype, including jaundice, rapid weight loss and a typically cholestatic liver biochemical profile of liver indicators similar to PFIC2 (Table 1). This observation of CsA-induced cholestasis in *bsep*$^{-/-}$ knockout (KO) mice indicates that Mdr1 is indeed a physiologically relevant bile salt transporter. However, the possibility remained that the cholestatic effects of CsA on *bsep*$^{-/-}$ mice are due to nonspecific toxicity of the compound rather than specific inhibition of Mdr1 mediated bile salt transport. CSA-treated wild-type mice were not noticeably affected by the treatment.

[00112] The serum biochemical profile for liver function of the TKO mice resembles PFIC2, and differs from that of *bsep*$^{-/-}$ mice in which no such abnormalities were seen (18). Examination of the plasma liver indicator profile of TKO mice showed low γ-GT, about 2-fold higher alkaline phosphatase (Table 1) and severe cholestasis comparable to the presentation of human PFIC2. The TKO mice had serum bilirubin levels on average about 13 times that of the wildtype controls. The changes in ALT and AST were relatively small, which again agrees with what is found in PFIC2 patients (27, 28), who usually have very poor biliary secretion of bile salt with high alkaline phosphatase and bilirubin, and low or normal γ-GT in serum. The TKO mice therefore are a good model for the physiological consequences of completely abolished bile salt secretion such as that found in human PFIC2.

Table 1. Liver biochemical indicators in bsep$^{-/-}$, and wildtype female mice treated with Cyclosporine A for two weeks, *bsep*$^{-/-}$ *mdr1a/b*$^{-/-}$ Triple Knockout mice, bsep$^{-/-}$, *mdr1a/b*$^{-/-}$, and wildtype female mice fed a normal diet or fed a 0.5% CA-supplemented diet (n = 4)

	Genotype	Bilirubin (mg/dl)	ALP (U/L)	γ-GT (U/L)	ALT (U/L)	AST (U/L)
CsA	*Bsep*$^{-/-}$	36.4 ± 0.783 (0.193E-10)	142 ± 1.14 (0.0128)	1.90 ± 1.96 (0.690)	59.9 ± 57.5 (0.0783)	106 ± 54.0 (0.663)
	WT	1.28 ± 0.262	93.2 ± 17.3	2.30 ± 0.984	11.4 ± 6.16	143 ± 102
Normal diet	TKO	18.2 ± 5.45 (0.193E-03)	409 ± 131 (0.871E-02)	1.52 ± 1.47 (0.120)	56.9 ± 35.9 (0.113)	150 ± 59.7 (0.584)
	Mdr1a/b$^{-/-}$	1.25 ± 0.397 (0.669)	64.8 ± 9.46 (0.202E-07)	4.15 ± 2.71 (0.667)	63.1 ± 64.6 (0.274)	168 ± 102 (0.509)
	bsep$^{-/-}$	0.935 ± 0.197 (0.0392)	277 ± 117 (0.174)	2.03 ± 1.01(0.298)	58.7 ± 50.1 (0.223)	71.5 ± 29.5 (0.265)
	WT	1.35 ± 0.245	185 ± 22.0	3.42 ± 2.22	24.2 ± 8.40	126 ± 82.9
CA diet	TKO	19.4 ± 3.34 (0.890E-08)	630 ± 121 (0.239E-06)	1.11 ± 0.521 (0.452)	300 ± 127 (0.121)	850 ± 296 (0.0427)
	Mdr1a/b$^{-/-}$	0.505 ± 0.125 (0.0848)	180 ± 31.3 (0.143)	0.467 ± 0.308 (0.116)	105 ± 21.0 (0.391)	179 ± 66.1 (0.322)
	Bsep$^{-/-}$	1.47 ± 0.384 (0.250)	697 ± 216 (0.330E-03)	0.822 ± 0.749 (0.310)	405 ± 86.5 (0.505E-02)	525 ± 139 (0.301)
	WT	1.07 ± 0.639	205 ± 19.7	1.81 ± 1.70	157 ± 128	344 ± 343

ALP – alkaline phosphatase
γGT – γ-Glutamyl Transpeptidase
ALT – Alanine aminotransferase
AST – Aspartate aminotransferase
CA – cholic acid
CsA – cyclosporine A
All numbers are expressed as a mean ± standard deviation (P value) (n = 3-6). Asterisks indicate statistical significance determined by two-tailed Student's t test between the knockout and the wild-type mice in the same group.

[00113] To evaluate the extent of molecular changes in the hepatocytes of the TKO mice, we measured their gene expression profiles using semi-quantitative real-time PCR. TKO mice displayed a typical cholestatic response, similar to what was found in the *bsep* KO mice (Figure 5). We found that Mrp3 and Mrp4, the major basolateral bile salt transporters for clearance of bile salt from hepatocytes into the sinusoidal blood circulation, are greatly upregulated, as is the gene most likely to function as the major bile salt hydroxylase, Cyp3a11. Down regulation of Cyp3a41 and Cyp3a44 were also noted. Surprisingly, real-time PCR also detected elevated *mdr1* transcription. We sequenced the residual *mdr1* transcripts and they consist of two alternatively spliced isoforms, the major one with an exon 4 deletion (SEQ ID NO: 4), directing translation of an N-terminal fragment of 38 amino acids, followed by a frame shift, coding sequence for 7 novel amino acids and a premature stop codon (SEQ ID NO: 5); the less abundant transcript has

a deletion of exons 4, 5, and 6 (SEQ ID NO: 6), resulting in translation of 38 original amino acids followed by a frame shift, 12 novel amino acids and a premature stop codon (SEQ ID NO: 7).

[00114] We also examined the expression of MDR1, along with some other ABC transporters, in PFIC patients of all subtypes. We reasoned that if MDR1 were indeed a physiologically relevant bile salt transporter in humans, intrahepatic bile salt accumulation in PFIC patients should result in MDR1 upregulation. If that were the case, one could stimulate the bile salt transport activity mediated by MDR1 clinically, to alleviate cholestasis. We compared liver biopsies from pediatric PFIC patients from six age-matched controls with non-cholestatic liver diseases, including glycogen storage disease, urea cycle disorders, hepatitis, and a non-tumor liver sample from a hepatoblastoma patient. The controls were not expected to have biliary secretion abnormalities. Assay by quantitative real-time PCR of the biopsy samples revealed a significant increase of MDR1 expression in PFIC patients to approximately four times greater than the average control (Table 2). This increased expression of MDR1 was further confirmed by immunofluorescent staining where a significant increase of human BSEP protein was detected in the canalicular membrane of the PFIC patients (Figure 6). The results indicate the presence of a physiologically redundant system for biliary bile salt secretion in both mouse and man.

Table 2. Relative expression levels of canalicular transporters in PFIC patients in comparison to age-matched controls

	age	ABCB1 (MDR1)	BSEP (BSEP)	ABCB4 (MDR3)	ABCC2 (MRP2)	ABCC3 (MRP3)	ABCC4 (MRP4)
PFIC-1							
I694N	10m	2.426	8.826	12.303	1.318	0.947	3.350
185-282del	5m	3.129	9.272	11.322	1.871	0.517	4.380
Q1131X/556-628del	7m	1.221	12.249	12.479	0.838	0.360	16.618
PFIC-2							
V284L/1145T del	8m	1.053	2.780	5.397	1.009	1.320	2.854
V284L/1145T del	14m	1.327	2.638	12.887	0.843	1.511	2.198
G1004D/R487H	8m	1.879	5.189	5.661	1.377	1.523	3.147
PFIC-3							
A *	5m	2.105	4.597	2.323	0.527	0.937	0.879
B *	2m	2.532	2.119	1.636	0.666	0.958	4.537
287-1005del	6.5y	3.300	2.979	1.346	0.960	1.540	1.899
Paediatric control (n=6)		0.365±0.074	3.019±0.466	2.071±0.484	1.818±0.589	0.963±0.279	0.729±0.244

* PFIC-3 patients diagnosed by their pathological and biochemical presentation.
Relative mRNA levels of transporters are expressed as fold change relative to TBP mRNA levels in each sample (Mean ± SD for controls).

[00115] The properties of mutant mice were compared to PFIC2 patients (Table 3).

TABLE 3

Phenotypes	***Bsep* KO**	**Triple KO**	**PFIC2**
PGP(MDR1) expression	Very high	no	Very high
Liver Size	enlarged	enlarged	Enlarged
Bile acids in bile	¼ of normal	--	<1% of normal
Bile flow	Near normal	blocked	--
Jaundice	no	severe	severe
GGT	normal	low or normal	low or normal
ALP/ALT/AST	normal	high	high

[00116] A significant upregulation of BSEP expression was found in livers of PFIC patients.

[00117] **EXAMPLE 2: Synthesis of taurine-conjugated 3α, 6β, 7β, 12α-hydroxy bile acid**

[00118] A taurine-conjugated 3α, 6β, 7β, 12α-hydroxy bile acid, essentially a 12α-hydroxylated version of β–muricholate, was synthesised as set out in (29-31). Isomers were produced simultaneously in the synthesis, and were likely to have similar activities. Therefore, at least five additional derivatives, specifically 3α, 6α, 7α, 12α-; 3α, 6β, 7α, 12α-; 3α, 6α, 7β, 12α-; 3α, 6β, 7β, 12α-; 3α, 6α, 7α, 12β-hydroxy derivatives of the above compound were also isolated. The isolated compounds were labeled using is ^{3}H-labelling bile salts by hydrogen exchange in a solution of tritium-enriched water, followed by re-isolation of the labeled bile salt (a service available from Perkin-Elmer, for example) (32). The isolated compounds were tested for their relative affinities for transport *via* MDR1 *in vitro*, as described herein. The most efficacious compound *in vitro* was isolated in larger quantities and used as the lead compound for the *in vivo* tests of toxicity and efficacy described herein or known in the art.

[00119] **1. Synthesis of taurine-conjugated 3α, 6α, 7α, 12α-tetrahydroxy-5β cholanoic acid**

Referring to Figure 10, 3α,6α,7α,12α-tetrahydroxy-5β-cholanoic acid (**7**) was protected as an acetate (**16**). Under an N_2 atmosphere, taurine was activated with N-hydroxysuccinimide in the presence of organic base and acetate (**16**), worked up with 0.1 N NaOH and washed through Serdolit^{TM}-1, to provide amide (**17**). Amide (**17**) was treated with 1 N NaOH, for 40 minutes at 80°C, followed by 20 minute at 50°C, and 1.5 hr at 25°C; yielding taurine conjugate (**18**) after washing through Serdolit^{TM}-1. ^{1}H-NMR spectrum of taurine conjugated 3α, 6α, 7α, 12α-tetrahydroxy-5β cholanoic acid (**18**) is shown in Figure 11.

[00120] **EXAMPLE 3: Evaluation of transport kinetics and interactions**

[00121] The transport kinetics and interactions of compounds, produced as described herein, with their transporter MDR1, are evaluated in comparison to the widely used therapeutic bile acid ursodeoxycholate as well as taurocholate, the primary bile acid in humans and mice and β-muricholate, a tri-hydroxy bile acid not normally found in humans. Membrane vesicle systems derived from CHO B30 cell membranes, a line of Chinese Hamster Ovary cells selected for its considerable amplification of the Mdr1 locus and corresponding drug resistance are used, as well as vesicles from the human SKOV series of cell lines, also selected for MDR1 overexpression. This experimental system is well established. Using this system ATP-dependent uptake of ^{3}H-labeled bile acids into vesicles, either alone or in combination with interacting compounds such as taurocholate or ursodeoxycholate, is measured. Humans and rodents do not differ significantly in the drug-resistance profiles mediated by their respective MDR1 P-glycoproteins, therefore using both human and rodent-cell derived vesicles confirms that any differences in novel bile acid transport kinetics between the species does not significantly alter their expected utility. Any bile acid less hydrophobic (and therefore less toxic) than taurocholate, but with a higher affinity than taurocholate (lower K_m) for transport by MDR1 is of potential therapeutic benefit e.g., tetra-hydroxylated bile acids show a suitable mix of low-toxicity and high capacity for transport by MDR1.

[00122] Modulation of transporter affinity for bile salts is also a mechanism by which muricholates and tetra-hydroxylated bile acids overcome cholestasis. A bile acid according to the invention may allosterically reduce the K_m of MDR1 for cholate, and so further increase its value as a choleretic agent. Such effects on MDR1 are examined using isolated membrane vesicles in

the presence of the various bile acids and also potential stimulators such as rhodamine 123, Hoechst 33342 or prazosin, known to interact with Mdr1 at separate sites (33-35). Uptake kinetics of commercially available ^{14}C-taurocholate into B30 membrane vesicles in the presence of various concentrations of potential modulators are compared. Positive modulation increases the uptake rate. Drugs known to be Mdr1 substrates are screened. Drug-bile acid and bile acid-bile acid interactions are characterized to determine if the K_m for taurocholate transport has decreased.

[00123] **EXAMPLE 4: Determination of maximum tolerated dose in vivo**

[00124] The maximum tolerated dose of bile acid according to the invention was determined. This test is carried out in two ways. First, as a pilot experiment of bile duct cannulation, a bolus of bile acid was infused into mice under anesthesia to measure its acute toxicity to animals. The responses of mice such as breath rate, bile flow rate, histological changes by H&E staining and the like were recorded. For taurocholate our tests indicated that 167 μmol /kg of body weight delivered intravenously, was the maximum tolerated dosage. Using this tolerance level as a reference point, the acute toxicity of the bile acid was determined. The maximum tolerated dosage (MTD) for intravenously administered ursodeoxycholate was found to be 65 μmol/kg of body weight. This is consistent with it being a less toxic bile salt. The LD50 for intravenously administered ursodeoxycholate in mice has been reported to be ~600 μmol/kg.

[00125] Therapeutic doses of ursodeoxycholate in humans are usually given orally and typically do not exceed 40μmol/kg/ of body weight per day. Further, orally administered bile acid may be less toxic as it enters the bloodstream and thus the liver at a slower rate than would occur with intravenous administration. The oral LD50 for ursodeoxycholate in rodents is at least 15 times greater than when given intravenously, giving considerable safety margin against overdose. Bile acids showing even greater affinity for Mdr1 than muricholates or cholates have a greater dose-specific effect on enhancing bile flow under conditions of Bsep dysfunction, while demonstrating lower toxicity at any given dose.

[00126] Chronic toxicity is tested by supplementing the diets of mice (wild-type as well as the hypersensitive *bsep* KO mice) with 0.1%-0.5% β-muricholate or bile acid according to the invention. Control feeding experiments use cholate as well as ursodeoxycholate. Wild-type mice can endure the extra bile salt loading of a 0.5% cholate indefinitely, while the same diet will

cause female *bsep* KO mice to lose weight, and kills male *bsep* KO mice within 10 days (16, 18). A 0.5% cholate diet will kill even female TKO mice within a week (36). Animals are fed control and bile acid-supplemented diets and monitored daily for weight loss and weekly for serum indicators of liver function to detect symptoms of cholestasis such as elevated liver enzymes in blood, as well as elevated bile salts and/or bilirubin (Table 1). Bile duct cannulations are also conducted in which a bolus of ^{14}C-taurocholate is injected into the tail veins of mice, either alone or together with a novel bile acid, and the kinetics of ^{14}C-taurocholate appearance in the bile measured and the *in vivo* effect of each novel bile acid upon taurocholate transport by Mdr1 and/or Bsep is evaluated.

[00127] **EXAMPLE 5: Amelioration of cholestasis in vivo**

[00128] The effectiveness of bile acids according to the invention is assessed in a whole animal system that allows the influence of molecular and physiological events affecting bile salt transport and bile flow. A combination of unique knockout mouse lines is used to test whether the novel bile salts can alleviate the cholestatic stress by promoting Mdr1-mediated bile flow. Three lines of KO mice are used. As described herein, the *bsep* KO mouse carries an inactivated *bsep* gene but has elevated *mdr1a/1b* expression; the *mdr1a/mdr1b* double KO mouse have normal *bsep* expression but inactivated *mdr1a/1b* genes; and the *bsep/mdr1a/mdr1b* triple KO mouse (TKO) has all three genes inactivated. These three lines of animals are used to verify the *in vivo* choleretic function of the novel bile acid in alleviating cholestatic pressure.

[00129] Small amounts of ^{3}H-labelled THBAs, of various isomers, prepared as described herein, are injected into the mutant mouse strains (plus wild-type controls), and radioactivity recovered in blood, urine, bile and hepatocytes are measured in order to compare the *in vivo* kinetics of the novel THBAs to those obtained for the same compounds *in vitro*, as described herein. The mice are challenged with a high dose of a bile acid according to the invention, selected on the basis of the kinetic experiments described above. Concentrations of 0.5% - 1.5% are used in the diet, given that the same amount of taurocholate (a substrate preferred by Bsep) can be tolerated indefinitely by wild-type mice. The mice are monitored according to their body weight, morbidity, mortality, liver indicator profile, and liver histology as reported previously (16, 18, 37) (Table 1). In addition, the bile of animals being fed the bile acid according to the invention is collected, and analyzed by HPLC. Increase in the amount of bile flow is a direct measure of the choleretic potential of the bile acid according to the invention, and changes in the

bile acid composition of bile in the three KO mouse strains indicate the extent to which bile acid according to the invention is transported by Mdr1 versus Bsep *in vivo*. Changes in the proportions of biliary bile acids other than the bile acid according to the invention itself, if observed, indicate modulatory effects of the bile acid according to the invention on the transport or synthesis of the conventional bile acid pool.

[00130] High dose feeding has fewer negative effects than taurocholate on *bsep* KO mice, moderate toxicity towards *mdr1a/1b* mice and high toxicity for TKO mice. Previously, we have found that *bsep* KO and TKO mice are hypersensitive to taurocholate feeding. If feeding with the novel bile acid according to the invention is less toxic to *bsep* KO mice than taurocholate feeding, we will then challenge our mutant mice with mixtures of the bile acid according to the invention and cholate or ursodeoxycholate in order to provide direct *in vivo* evidence for the therapeutic value of the bile acid according to the invention.

[00131] **EXAMPLE 6: Synthesis of 3α,6α,7α,12α-tetrahydroxy-5β-cholanoic acid and 3α,6β,7α,12α-tetrahydroxy-5β-cholanoic acid**

[00132] Three forms of bile acid were synthesized: 3α, 6α, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid, 3α, 6β, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid and 3α, 6β, 7β, 12α-tetrahydroxy-5β-cholan-24-oic acid. The following syntheses are based on those reported by Iida *et al.* and Aggarwal *et al.* (61, 62, and references cited therein), and Gouin *et al.*, Fieser *et al.*, Putz *et al.*, Narasimhan *et al.* and Ornatein *et al.* (66-70 and references cited therein). This chemistry has been performed on a multi-gram scale and minor modifications have been made to the experimental and purification procedures in order to optimize yields. The final compounds were purified by flash chromatography and were greater than 95% pure (as indicated by NMR analysis). They have also been shown to be homogeneous by HPLC methods.

[00133] **Synthesis of 3α,6α,7α,12α-tetrahydroxy-5β-cholanoic acid**



3α,6α,7α,12α-tetrahydroxy-5β-cholanoic acid

[00134] Protection of cholic acid (**1**) afforded the methyl ester (**2**) that was oxidized with *N*-bromosuccinimide (NBS) to the corresponding ketone (**3**). This compound was then protected as the diacetate (**4**) and converted to the key intermediate (**5**) on reaction with molecular bromine. This bromide was then hydrolyzed to the hydroxyl-ketone (**6**). Subsequent reduction and global deprotection of the acetate and methyl ester moieties afforded the target compound (**7**).

[00135] **Synthesis of 3α,6β,7α,12α-tetrahydroxy-5β-cholanoic acid.**



3α,6β,7α,12α-tetrahydroxy-5β-cholanoic acid

[00136] The intermediate (**5**), see above, was reduced with zinc borohydride and the resultant bromohydrin was reduced further with metallic zinc to afford the corresponding alkene (**8**). Treatment of the latter compound with *meta*-chloroperoxybenzoic acid (*m*-CPBA) afforded the epoxide (**9**). Lewis acid-mediated ring opening of this compound afforded the diol (**10**). Subsequent global deprotection afforded the target compound (**11**).

[00137] **Alternate method of synthesis of 3α,6α,7α,12α-tetrahydroxy-5β-cholanoic acid**

[00138] Referring to Figure 9, oxidation of cholic acid (**1**) with NBS provided corresponding ketone (**12**) followed by protection to afford the corresponding methyl ester (**3**). This compound was then protected as an acetate (**4'**), and subsequently, acetate (**4**) and converted to intermediate (**5**) by reaction with molecular bromine. The bromide was hydrolyzed to the hydroxyl-ketone (**13**). Subsequent reduction and deprotection afforded the target compound (**7**).

[00139] **EXAMPLE 7. 3α, 6α, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid stimulates bile flow rate (BFR) in wild-type mice**

[00140] For bile duct cannulation, wild type mice on the genetic background of FVB/NJ were weighed and anesthetized by intraperitoneal injection of Ketamine (112.5 mg/kg) and Xylazine (11.3 mg/kg) after 2-4 hours of fasting. The abdomen was opened, and the gall bladder was cannulated using a PE-10 catheter after distal common bile duct ligation [63, 64]. After 20 minutes of bile flow equilibration, bile was collected into pre-weighed tubes at 5-minute intervals for 10 minutes. A bolus of 3α, 6α, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid (6α, 7α THBA, pH.7.4-7.6), 3α, 6β, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid (6β, 7α THBA, pH.7.4-7.6), ursodeoxycholic acid (UDC, pH.7.4-7.6) or cholic acid (100 μmol/kg body weight) was then infused into the tail vein over a 20-second interval. Bile was then further collected through the cannula at 2-minute intervals for 10 or 20 minutes, followed by 10-minute intervals for 30 minutes. The bile flow rate was calculated by weighing the tubes containing the collected bile. Bile collected was used for HPLC analysis.

[00141] UDC solution for the infusion was freshly made within 2 hours prior to the experiments, and was made as follows: for each milliliter of 100 mM UDC solution, 39.62 mg of UDC (Sigma U5127) was vortex-mixed in sequence with 86.6 μl of 100% ethanol, 86.6 μl of 1N NaOH, and 826 μl of 0.9% NaCl solution. Different working solution are diluted from the 100mM solution. The pH of the solution was 7.4-7.6.

[00142] Figure 7 demonstrates that 3α, 6α, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid stimulates bile flow rate (BFR) in wild-type mice. (A) BFR as a function of body weight in mice after infusion of 3α, 6α, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid (THBA). (B) BFR as a function of body weight in mice after infusion of cholic acid (CA) (3α, 7α, 12α-trihydroxy-5β-cholan-24-oic acid). A bolus of THBA or CA (100 μmol/kg body weight) was infused into the tail vein over a 20 second interval at 10 minutes. Results are presented as the mean (μl/100g of body weight) ± the standard deviation.

[00143] Bile flow rate (BFR) was determined before and after infusion of 3α, 6β 7α 12α tetrahydroxy cholanoic acid (6β, 7αTHBA) at a dose of 65, 250, 350 and 400 μmol/kg body weight (BW) (Figure 12A); or infusion of 3α, 6α 7α 12α THBA (6α, 7α THBA) of 65 and 200 μmol/kg BW (Figure 12B). Figure 12C illustrates BFR as a function of body weight before and

after the infusion of 65 μmol/kg body weight of 6β, 7αTHBA, 6α, 7α THBA and ursodeoxycholic acid (UDC). Results are represented as the mean ± the standard deviation of three mice.

[00144] During bile duct cannulation experiments, we have found that UDC infused through the tail vein at a concentration of 70 μmol/kg body weight or higher caused death of wild-type mice under anesthesia (Ketamine, 112.5 mg/kg and Xylazine, 11.3 mg/kg). We thus determined that UDC at 65 μmol/kg of body weight as administrated through a bolus tail vein infusion was the maximum tolerated dose (MTD) in the mice. However, the wild-type mice can tolerate 6β, 7α THBA infusion at 500 μmol/kg of body weight (highest dosage tested) and 6α, 7α THBA infusion at 400 μmol/kg of body weight (highest dosage tested) without death. The maximum tolerated doses of 6β, 7αTHBA (MTD>500 μmol/kg of body weight) and 6α, 7α THBA (MTD>400 μmol/kg of body weight) were several times higher than that of UDC.

[00145] UDC at 65 μmol/kg body weight is the maximum tolerated dose (MTD) in the mice, resulting in a bile flow rate similar to that observed by infusion of a similar quantity of 6β, 7αTHBA or 6α, 7α THBA. Infusion of increasing quantities of 6β, 7αTHBA or 6α, 7α THBA, results in a corresponding increase in bile flow rate (Figures 12 A, B).

[00146] Figure 8 demonstrates HPLC (High Performance Liquid Chromatography) profiles of bile fractions collected from a wild-type mouse before (A), and 2-4 minutes after (B), infusion (100 μmol/kg) of 3α, 6α, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid. Figure 8C shows HPLC profiles of bile fractions collected from a wild-type mouse before (upper trace), and 2-4 minutes after (lower trace), infusion (100 mmol/kg) of cholic acid.

[00147] HPLC was carried out with a Waters 600 pump and controller and a 486 UV detector. Separation was performed on a Spherisorb S5 ODS2 C-18 (5 mm particle size, 250 mm x 4 mm, Waters) reverse phase analytical column and was preceded by guard column (Nova Pack, Waters). Integration of the peaks was carried out using Millennium 2010 software. The bile salt controls were separated at ambient temperature over 48 minutes at a flow rate of 0.6 mL/min and 3200 psi. The mobile phase consisted of solvent A (MeOH) and solvent B (60:40 MeOH: 0.01 M potassium phosphate, 0.02 M sodium phosphate (pH 5.35 (modified from Rossi et al. 1987 *J Lipid Res* **28**(5): 589-95 (71); Hagey et al. 1998. *J Lipid Res* **39**(11): 2119-24, (72)) . Initial conditions were held at 100% B for the first 25 minutes. Over the next 10 minutes, there was a linear gradient to 30% B and conditions were held for another 5 minutes. The conditions

then decreased through a linear gradient to 100% A over 8 minutes. The system was flushed with 100% MeOH followed by equilibration back to the initial conditions. The effluent was monitored at 210 nm.

[00148] For visualizing the 3α, 6α, 7α, 12α-THBA, 4 μl bile was dissolved in 20ul methanol, and injected into a buffer stream at 0.6mL/minute, and read by absorbance at a wavelength of 210nm. The buffer was 60% methanol, 40% 0.1M KH_2PO_4, 0.02M NaH_2PO_4 pH5.35 [65]. For visualizing cholic acid, the procedure was the same as for 3α, 6α, 7α, 12α-THBA initially, but after 5 minutes the buffer was stepped linearly to a mixture of 20% methanol:80% buffer within 4 minutes, held constant for another 10 minutes, then stepped linearly within 2 minutes to 30% methanol:70% buffer for the duration of the run.

[00149] Therefore, tetrahydroxy-5β-cholan-24-oic acids (3α, 6α, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid) promotes bile flow in wild-type mice. As demonstrated by High Performance Liquid Chromatography (HPLC), 3α, 6α, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid is metabolized by taurine-conjugation *in vivo* and secreted into the bile minutes after being infused into the mouse tail vein (Figure 8A, B). This suggests that this bile acid can be metabolized and detoxified by the same pathways that metabolize native bile acids and mediate their secretion across the canalicular membrane.

[00150] **EXAMPLE 8: Synthesis of 2α,3α,7α,12α-tetrahydroxy-5β-cholanoic acid and 3α,4α,7α,12α-tetrahydroxy-5β-cholanoic acid**

[00151] 2α,3α,7α,12α-tetrahydroxy-5β-cholanoic acid was synthesized from cholic acid as follows:



[00152] Further polyhydroxylated bile acids are synthesized, using methods as described in, for example, Tserng KY and Klein PD (1977) (74), Leppik RA (1983) (75), Iida T. et al. (1990) (76) or Iida T. et al. (1991) (77). The synthesis scheme is as follows, where Compound A is a 2α,3α,7α,12α-tetrahydroxy-5β-cholanoic acid and Compound B is a 3α,4α,7α,12α-tetrahydroxy-5β-cholanoic acid:



a. HCOOH, $HClO_4$, Ac_2O b. NH_3OH, MeOH, c.Jones reagent d. $MeOH/H^+$, e. Ac_2O, Py, f. Br_2/AcOH g. KOAc/AcOH h. tert-butylamine-borane complex i. KOH/MeOH, r.t.,

[00153] An alternate synthesis scheme for 3α,4α,7α,12α-tetrahydroxy-5β-cholanoic acid is as follows:



References

1. Strautnieks, S. S., Bull, L. N., Knisely, A. S., Kocoshis, S. A., Dahl, N., Arnell, H., Sokal, E., Dahan, K., Childs, S., Ling, V., Tanner, M. S., Kagalwalla, A. F., Nemeth, A., Pawlowska, J., Baker, A., Mieli-Vergani, G., Freimer, N. B., Gardiner, R. M. & Thompson, R. J. (1998) *Nat Genet* **20,** 233-8.
2. Jansen, P. L., Strautnieks, S. S., Jacquemin, E., Hadchouel, M., Sokal, E. M., Hooiveld, G. J., Koning, J. H., De Jager-Krikken, A., Kuipers, F., Stellaard, F., Bijleveld, C. M., Gouw, A., Van Goor, H., Thompson, R. J. & Muller, M. (1999) *Gastroenterology* **117,** 1370-9.
3. Fattinger, K., Funk, C., Pantze, M., Weber, C., Reichen, J., Stieger, B. & Meier, P. J. (2001) *Clin Pharmacol Ther* **69,** 223-31.
4. Funk, C., Pantze, M., Jehle, L., Ponelle, C., Scheuermann, G., Lazendic, M. & Gasser, R. (2001) *Toxicology* **167,** 83-98.
5. Funk, C., Ponelle, C., Scheuermann, G. & Pantze, M. (2001) *Mol Pharmacol* **59,** 627-35.
6. Stieger, B., Fattinger, K., Madon, J., Kullak-Ublick, G. A. & Meier, P. J. (2000) *Gastroenterology* **118,** 422-30.
7. van Mil, S. W., Klomp, L. W., Bull, L. N. & Houwen, R. H. (2001) *Semin Liver Dis* **21,** 535-44.
8. Kubitz, R., Keitel, V., Scheuring, S., Kohrer, K. & Haussinger, D. (2006) *J Clin Gastroenterol* **40,** 171-5.
9. Vallejo, M., Briz, O., Serrano, M. A., Monte, M. J. & Marin, J. J. (2006) *J Hepatol* **44,** 1150-7.
10. Keitel, V., Vogt, C., Haussinger, D. & Kubitz, R. (2006) *Gastroenterology* **131,** 624-9.
11. Green, R. M., Hoda, F. & Ward, K. L. (2000) *Gene* **241,** 117-23.
12. Byrne, J. A., Strautnieks, S. S., Mieli-Vergani, G., Higgins, C. F., Linton, K. J. & Thompson, R. J. (2002) *Gastroenterology* **123,** 1649-58.
13. Gerloff, T., Stieger, B., Hagenbuch, B., Madon, J., Landmann, L., Roth, J., Hofmann, A. F. & Meier, P. J. (1998) *J Biol Chem* **273,** 10046-50.
14. Noe, J., Stieger, B. & Meier, P. J. (2002) *Gastroenterology* **123,** 1659-66.
15. Gerloff, T., Meier, P. J. & Stieger, B. (1998) *Liver* **18,** 306-12.

16. Wang, R., Lam, P., Liu, L., Forrest, D., Yousef, I. M., Mignault, D., Phillips, M. J. & Ling, V. (2003) *Hepatology* **38,** 1489-99.
17. Stieger, B., O'Neill, B. & Meier, P. J. (1992) *Biochem J* **284 (Pt 1),** 67-74.
18. Wang, R., Salem, M., Yousef, I. M., Tuchweber, B., Lam, P., Childs, S. J., Helgason, C. D., Ackerley, C., Phillips, M. J. & Ling, V. (2001) *Proc Natl Acad Sci U S A* **98,** 2011-6.
19. Lam, P., Wang, R. & Ling, V. (2004) in *Falk Symposium No 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications* (Kluwer Academic, Dordrecht).
20. Lam, P., Wang, R. & Ling, V. (2005) *Biochemistry* **44,** 12598-605.
21. Asamoto, Y., Tazuma, S., Ochi, H., Chayama, K. & Suzuki, H. (2001) *Biochem J* **359,** 605-10.
22. Schinkel, A. H., Mayer, U., Wagenaar, E., Mol, C. A., van Deemter, L., Smit, J. J., van der Valk, M. A., Voordouw, A. C., Spits, H., van Tellingen, O., Zijlmans, J. M., Fibbe, W. E. & Borst, P. (1997) *Proc Natl Acad Sci U S A* **94,** 4028-33.
23. Hofmann, A. F. (1999) *Arch Intern Med* **159,** 2647-58.
24. Hofmann, A. F. (2001) *Hepatology* **34,** 848-50.
25. Tsukada, N., Azuma, T. & Phillips, M. J. (1994) *Proc Natl Acad Sci U S A* **91,** 6919-23.
26. Chen, H. L., Chen, H. L., Liu, Y. J., Feng, C. H., Wu, C. Y., Shyu, M. K., Yuan, R. H. & Chang, M. H. (2005) *J Hepatol* **43,** 472-7.
27. Knisely, A. S. (2000) *Pediatr Dev Pathol* **3,** 113-25.
28. Jacquemin, E. (2000) *Clin Liver Dis* **4,** 753-63.
29. Matoba, N., Mosbach, E. H., Cohen, B. I., Une, M. & McSherry, C. K. (1989) *J Lipid Res* **30,** 1005-14.
30. Kihira, K., Yoshii, M., Okamoto, A., Ikawa, S., Ishii, H. & Hoshita, T. (1990) *J Lipid Res* **31,** 1323-6.
31. Kakiyama, G., Iida, T., Yoshimoto, A., Goto, T., Mano, N., Goto, J., Nambara, T., Hagey, L. R. & Hofmann, A. F. (2004) *J Lipid Res* **45,** 567-73.
32. Shapiro, A. B., Corder, A. B. & Ling, V. (1997) *Eur J Biochem* **250,** 115-21.
33. Shapiro, A. B., Fox, K., Lam, P. & Ling, V. (1999) *Eur J Biochem* **259,** 841-50.
34. Shapiro, A. B. & Ling, V. (1997) *Eur J Biochem* **250,** 130-7.
35. Takikawa, H., Sano, N., Aiso, M., Takamori, Y. & Yamanaka, M. (1997) *J Gastroenterol Hepatol* **12,** 84-6.
36. Wang, R., Chen, H.-L., Liu, L., Sheps, J. A., Low, C., Phillips, M. J. & Ling, V. (2007).
37. Rust C, Karnitz L M, Paya C V, Moscat J, Simari R D, Gores G J. J Biol Chem. 2000;275:20210–20216
38. Sodeman T, Bronk S F, Roberts P J, Miyoshi H, Gores G J. Am J Physiol Gastrointest Liver Physiol. 2000;278:G992–G999
39. Jones B A, Rao Y P, Stravitz R T, Gores G J. Am J Physiol. 1997;272:G1109–G1115
40. Kwo P, Patel T, Bronk S F, Gores G J. Am J Physiol. 1995;268:G613–G621
41. Rodrigues C M, Fan G, Ma X, Kren B T, Steer C J. J Clin Invest. 1998;101:2790–2799
42. Wang H, Chen J, Hollister K, Sowers L C, Forman B M. Mol Cell. 1999;3:543–553
43. Makishima M, Okamoto A Y, Repa J J, Tu H, Learned R M, Luk A, Hull M V, Lustig K D, Mangelsdorf D J, Shan B. Science. 1999;284:1362–1365
44. Chiang J Y, Kimmel R, Weinberger C, Stroup D. J Biol Chem. 2000;275:10918–10924
45. Parks D J, Blanchard S G, Bledsoe R K, Chandra G, Consler T G, Kliewer S A, Stimmel J B, Willson T M, Zavacki A M, Moore D D, et al. Science. 1999;284:1365–1368
46. Goodwin B, Jones S A, Price R R, Watson M A, McKee D D, Moore L B, Galardi C, Wilson J G, Lewis M C, Roth M E, et al. Mol Cell. 2000;6:517–526

47. Sinal C J, Tohkin M, Miyata M, Ward J M, Lambert G, Gonzalez F J. Cell. 2000;102:731–744
48. Hofmann A F. J Pediatr Gastroenterol Nutr, 1995; 20(4):376 90
49. Jansen P L and Sturm E. Liver Int 2003; 23(5):315-22
50. Childs, S.; Ling V. Important Adv Oncol. 1994;21-36
51. Hofmann A F, Sjovall J, Kurz G, Radominska A, Schteingart C D, Tint GS, Vlahcevic Z R, Setchell K D. J Lipid Res. 1992; 33(4):599-604.
52. Tohma, M, Mahara R, Takeshita H, Kurosawa T, Ikegawa S, Nittono H. Chem. Pharm. Bull. 1985;33(7):3071-3073
53. Iida T, Tamaru T, Chang F C, Goto J, Nambara T. Journal of Lipid Research 1991;32:649-658
54. Iida T, Komatsubara I, Chang F C, Goto J, Nambara T. Steroids 1991;56:114-122
55. Aggarwal S K, Batta A K, Salen G, Shefer S. Steroids 1992;57:107- 111
56. Iida T, Nishida S, Chang F C, Niwa T, Goto J, Nambara T. Steroids 1993;58:148-152
57. Kurosawa T, Nakano H, Sato M, Tohma M. Steroids 1995;60:439-444
58. Kurosawa T, Sato M, Nakano H, Tohma M. Steroids 1996;61:421-428
59. Iida T, Hikosaka M, Kakiyama G, Shiraishi K, Schteingart C D, Hagey L R, Ton-Nu H T, Hofmann A F, Mano N, Goto J, Nambara T. Chem. Pharm. Bull. 2002;50(10):1327-1334
60. Bohme, M., Muller, M., Leier, I., Jedlitschky, G. and Keppler, D. (1994) Cholestasis caused by inhibition of the adenosine triphosphate-dependent bile salt transport in rat liver. Gastroenterology 107, 255–265
61. Iida, T.; Komatsubara, I.; Yoda, S.; Goto, J.; Nambara, T.; Chang, F. C. *Steroids* **1990**, *55*, 531-539.62. Aggarwal, S. K.; Batta, A. K.; Salen, G.; Shefer, S. *Steroids* **1992**, *57*, 107-111.
63. Wang, R., et al., *Severe cholestasis induced by cholic acid feeding in knockout mice of sister of P-glycoprotein.* Hepatology, 2003. **38**(6): p. 1489-99.
64. Wang, R., et al., *Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis.* Proc Natl Acad Sci U S A, 2001. **98**(4): p. 2011-6.
65. Forrest, D.N., Bile Salt Hydroxylation as a mechanism for detoxification in spgp knockout mice. M.Sc. Thesis, University of British Columbia, 2003.
66. Gouin, S.; Zhu, X.X. Synthesis of 3!- and 3"-dimers from selected bile acids. Steroids 1996, 61, 664-669.
67. Fieser, L.F.; Rajagopalan, S. Selective oxidation with N-bromosuccinimide. I. Cholic acid. J. Am. Chem. Soc. 1949, 71, 3609-3614.
68. Pütz, G.; Schmide,r W.; Nitschk,e R.; Kurz, G.; Blum, H.E. Synthesis of phospholipid-conjugated bile salts and interaction of bile salt-coated liposomes with cultured hepatocytes. J. Llipid Res. 2005, 46, 2325-2338.
69. S. Narasimhan* and R. Balakumar Synthetic Applications of Zinc Borohydride, Aldrichmica acta, Vol. 31, No. 1, 1998 19
70. Paul L. Ornatein,* M. Brian Arnold, Nancy K. Augenstein, and Jonathan W. Pascha, Syntheses of 6-Oxodecahydroisoquinoline-3-carboxylates. Useful Intermediates for the Preparation of Conformationally Defined Excitatory Amino Acid Antagonists, J. Org. Chem., Vol. 56, No. 14, 1991 4389
71. Rossi, S. S., et al.. "High pressure liquid chromatographic analysis of conjugated bile acids in human bile: simultaneous resolution of sulfated and unsulfated lithocholyl amidates and the common conjugated bile acids." 1987. *J Lipid Res* **28**(5): 589-95
72. Hagey, L. R., et al.. "An N-acyl glycyltaurine conjugate of deoxycholic acid in the biliary bile acids of the rabbit." 1998. *J Lipid Res* **39**(11): 2119-24.

73. Chen HL, et al. Progressive familial intrahepatic cholestasis with high gamma-glutamyltranspeptidase levels in Taiwanese infants: role of MDR3 gene defect? 2001. *Pediatr Res.* **50**:50-5.
74. Tserng KY and Klein PD. "Formylated bile acids: improved synthesis, properties, and partial deformylation." 1977 Steroids, 29: 635-648
75. Leppik RA. "Improved synthesis of 3-keto, 4-ene-3-keto, and 4,6-diene-3-keto bile acids." 1983 Steroids, 41: 475-484
76. Iida T. et al. "Potential bile acid metabolites. 17. Synthesis of 2 beta-hydroxylated bile acids." 1991 Steroids, 56: 114-122
77. Iida T. et al. "Potential bile acid metabolites. 116. Synthesis of stereoisomeric 3 alpha,6,7,12 alpha-tetrahydroxy-5 beta-cholanoic acids."1990 Steroids, 55: 530-539.

[00154] **Other Embodiments**

[00155] The present invention has been described with regard to one or more embodiments. However, it will be apparent to persons skilled in the art that a number of variations and modifications can be made without departing from the scope of the invention as defined in the claims. Therefore, although various embodiments of the invention are disclosed herein, many adaptations and modifications may be made within the scope of the invention in accordance with the common general knowledge of those skilled in this art. Such modifications include the substitution of known equivalents for any aspect of the invention in order to achieve the same result in substantially the same way. Numeric ranges are inclusive of the numbers defining the range. In the specification, the word "comprising" is used as an open-ended term, substantially equivalent to the phrase "including, but not limited to," and the word "comprises" has a corresponding meaning. Citation of references herein shall not be construed as an admission that such references are prior art to the present invention. All publications are incorporated herein by reference as if each individual publication was specifically and individually indicated to be incorporated by reference herein and as though fully set forth herein. The invention includes all embodiments and variations substantially as hereinbefore described and with reference to the examples and drawings.

WHAT IS CLAIMED IS:

1. A method of treating a biliary disorder or stimulating bile flow in a subject in need thereof, the method comprising administering a therapeutically effective amount of a compound according to Formula I:



or a derivative thereof, wherein

any one of R_1 to R_9 may be –H or –OH, provided that at least four of R_1 to R_9 are –OH; and

R_{10} may be –COOH or $-CH_2OH$.

2. The method of claim 1 wherein said compound comprises a hydrophilicity greater than that of cholate.

3. The method of claim 1 or 2 wherein said compound is selected from the group consisting of a tetrahydroxylated bile acid and a pentahydroxylated bile acid, or a derivative thereof.

4. The method of claim 3 wherein said tetrahydroxylated bile acid is selected from the group consisting of :

a 3,6,7,12-tetrahydroxycholanoic acid,

a 3,4,7,12-tetrahydroxycholanoic acid,

a 1,3,7,12-tetrahydroxycholanoic acid,

a 2,3,7,12-tetrahydroxycholanoic acid,

a 3,7,16,24-tetrahydroxycholanoic acid, and

a 3,7,15,24-tetrahydroxycholanoic acid,

or a derivative thereof.

5. The method of claim 4 wherein said 3,6,7,12-tetrahydroxycholanoic acid is selected from the group consisting of:

a 3α, 6α, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid,
a 3α, 6β, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid,
a 3α, 6α, 7β, 12α-tetrahydroxy-5β-cholan-24-oic acid,
a 3α, 6β, 7β, 12α-tetrahydroxy-5β-cholan-24-oic acid,
a 3α, 6α, 7α, 12β-tetrahydroxy-5β-cholan-24-oic acid,
a 3α, 6β, 7α, 12β-tetrahydroxy-5β-cholan-24-oic acid, and
a 3α, 6β, 7β, 12β-tetrahydroxy-5β-cholan-24-oic acid,

or wherein said 2,3,7,12-tetrahydroxycholanoic acid is 2α,3α,7α,12α-tetrahydroxy-5β-cholanoic acid,

or wherein said a 3,4,7,12-tetrahydroxycholanoic acid is 3α,4α,7α,12α-tetrahydroxy-5β-cholanoic acid,

or a derivative thereof.

6. The method of any of claims 1 to 5 wherein said compound has a preferential affinity for MDR1 when compared to BSEP.

7. The method of any of claims 1 to 6 wherein said compound has a high affinity for MDR1.

8. The method of any of claims 1 to 7 wherein said compound is a conjugated compound.

9. The method of claim 8 wherein said conjugated compound is a taurine or a glycine conjugate.

10. The method of claim 1 wherein said compound is selected from the group consisting of

a tauryl or glycyl conjugate of a 3α, 6β, 7α, 12β-tetrahydroxy-5β-cholan-24-oic acid,
a tauryl or glycyl conjugate of a 3α, 6β, 7β, 12β-tetrahydroxy-5β-cholan-24-oic acid, and
a tauryl conjugate of a 3α, 6β, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid.

11. The method of claim 1 wherein said compound is a tauryl conjugate of a 3α, 6β, 7β, 12α-tetrahydroxy-5β-cholan-24-oic acid.

12. The method of any one of claims 1 to 11 further comprising administering at least one other therapeutic agent.

13. The method of claim 12 wherein said other therapeutic agent has a preferential affinity for BSEP.

14. The method of claim 12 or 13 wherein said other therapeutic agent is ursodeoxycholate.

15. The method of any one of claims 1 to 14 wherein said biliary disorder is selected from the group consisting of benign biliary strictures, benign pancreatic disease cysts, diverticulitis, liver fibrosis, liver damage, common bile duct stones, pancreatitis, pancreatic cancer or pseudocyst, periampullary cancer, bile duct carcinoma, primary sclerosing cholangitis, autoimmune cholangitis, extrinsic duct compression (e.g., compression due to a mass or tumor on a nearby organ), viral hepatitis, sepsis, bacterial abscess, use of drugs e.g., drug-induced idiosyncratic hepatotoxicity, lymphoma, tuberculosis, metastatic carcinoma, sarcoidosis, amyloidosis, intravenous feeding, primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic hepatitis with or without cirrhosis, nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, chronic hepatitis with or without cirrhosis, intrahepatic cholestasis of pregnancy, biliary calculosis, biliary dyscinesia, Sjogren syndrome, Wilson's disease, ischemia, toxins, alcohol, acute liver failure, α1-antitrypsin deficiency, PFIC2, Benign Recurrent Intrahepatic Cholestasis, hepatocellular carcinoma, portal hypertension, veno-occlusive disease, and hepatic vein thrombosis.

16. The method of any one of claims 1 to 14 wherein said biliary disorder arises or potentially arises from cholestasis.

17. The method of any one of claims 1 to 16 wherein said subject is a human.

18. A pharmaceutical or nutritional composition comprising a compound according to Formula I:



or a derivative thereof, together with a pharmaceutically acceptable carrier, wherein

any one of R_1 to R_9 may be –H or –OH, provided that at least four of R_1 to R_9 are –OH; and

R_{10} may be –COOH or $-CH_2OH$.

19. The composition of claim 18, wherein said compound comprises a hydrophilicity greater than that of cholate.

20. The composition of claim 18 or 19, wherein said compound is selected from the group consisting of a tetrahydroxylated bile acid, a pentahydroxylated bile acid, or a derivative thereof.

21. The composition of claim 20, wherein said tetrahydroxylated bile acid is selected from the group consisting of:

a 3,6,7,12-tetrahydroxycholanoic acid,

a 3,4,7,12-tetrahydroxycholanoic acid,

a 1,3,7,12-tetrahydroxycholanoic acid,

a 2,3,7,12-tetrahydroxycholanoic acid,

a 3,7,16,24-tetrahydroxycholanoic acid, and

a 3,7,15,24-tetrahydroxycholanoic acid,

or a derivative thereof.

22. The composition of claim 21, wherein said 3,6,7,12-tetrahydroxycholanoic acid is selected from the group consisting of:

a 3α, 6α, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid,

a 3α, 6β, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid,

a 3α, 6α, 7β, 12α-tetrahydroxy-5β-cholan-24-oic acid,

a 3α, 6β, 7β, 12α-tetrahydroxy-5β-cholan-24-oic acid,

a 3α, 6α, 7α, 12β-tetrahydroxy-5β-cholan-24-oic acid,

a 3α, 6β, 7α, 12β-tetrahydroxy-5β-cholan-24-oic acid, and

a 3α, 6β, 7β, 12β-tetrahydroxy-5β-cholan-24-oic acid,

or wherein said 2,3,7,12-tetrahydroxycholanoic acid is 2α,3α,7α,12α-tetrahydroxy-5β-cholanoic acid,

or wherein said a 3,4,7,12-tetrahydroxycholanoic acid is 3α,4α,7α,12α-tetrahydroxy-5β-cholanoic acid,

or a derivative thereof.

23. The composition of any one of claims 18 to 22, wherein said compound has a preferential affinity for MDR1 when compared to BSEP.

24. The composition of any one of claims 18 to 23, wherein said compound has a high affinity for MDR1.

25. The composition of any one of claims 18 to 24, wherein said compound is a conjugated compound.

26. The composition of claim 25, wherein said conjugated compound is a taurine or a glycine conjugate.

27. The composition of claim 18, wherein said compound is selected from the group consisting of:

a tauryl or glycyl conjugate of a 3α, 6β, 7α, 12β-tetrahydroxy-5β-cholan-24-oic acid,

a tauryl or glycyl conjugate of a 3α, 6β, 7β, 12β-tetrahydroxy-5β-cholan-24-oic acid, and

a tauryl conjugate of a 3α, 6β, 7α, 12α-tetrahydroxy-5β-cholan-24-oic acid.

28. The composition of claim 18, wherein said compound is a tauryl conjugate of a 3α, 6β, 7β, 12α-tetrahydroxy-5β-cholan-24-oic acid.

29. The composition of any one of claims 18 to 28, further comprising at least one other therapeutic agent.

30. The composition of claim 29, wherein said other therapeutic agent has a preferential affinity for BSEP.

31. The composition of claim 29, wherein said other therapeutic agent is ursodeoxycholate.

32. Use of the composition of any one of claims 18 to 31 for the preparation of a medicament for treating a biliary disorder or stimulating bile flow.

33. The use of claim 32 wherein said biliary disorder is selected from the group consisting of benign biliary strictures, benign pancreatic disease cysts, diverticulitis, liver fibrosis, liver damage, common bile duct stones, pancreatitis, pancreatic cancer or pseudocyst, periampullary cancer, bile duct carcinoma, primary sclerosing cholangitis, autoimmune cholangitis, extrinsic duct compression (e.g., compression due to a mass or tumor on a nearby organ, viral hepatitis, sepsis, bacterial abscess, use of drugs e.g., drug-induced idiosyncratic hepatotoxicity, lymphoma, tuberculosis, metastatic carcinoma, sarcoidosis, amyloidosis, intravenous feeding, primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic hepatitis with or without cirrhosis, nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, chronic hepatitis with or without cirrhosis, intrahepatic cholestasis of pregnancy, biliary calculosis, biliary dyscinesia, Sjogren syndrome, Wilson's disease, ischemia, toxins, alcohol, acute liver failure, α1-antitrypsin deficiency, PFIC2, Benign Recurrent Intrahepatic Cholestasis, hepatocellular carcinoma, portal hypertension, veno-occlusive disease, and hepatic vein thrombosis.

34. The use of claim 28 wherein said biliary disorder arises or potentially arises from cholestasis.

35. The use of any one of claims 28 to 34 wherein said subject is a human.

36. An article of manufacture comprising a compound according to Formula I:



or a derivative thereof, together with instructions for use in treating a biliary disorder or stimulating bile flow, wherein

any one of R_1 to R_9 may be –H or –OH, provided that at least four of R_1 to R_9 are –OH; and

R_{10} may be –COOH or $-CH_2OH$.

37. The method of claim 4 or the composition of claim 20 wherein said 2,3,7,12-tetrahydroxycholanoic acid is a 2α,3α,7α,12α-tetrahydroxy-5β-cholanoic acid, or a derivative thereof.

38. The method of claim 4 or the composition of claim 20 wherein said 3,4,7,12-tetrahydroxycholanoic acid is a 3α,4α,7α,12α-tetrahydroxy-5β-cholanoic acid, or a derivative thereof.

39. A 2α,3α,7α,12α-tetrahydroxy-5β-cholanoic acid.

40. A 3α,4α,7α,12α-tetrahydroxy-5β-cholanoic acid.

Fig.1



Fig.2


a.
Survival rate
3-KO
spgp ko
b.
Relative body Weight
Triple ko
spgp ko
wt
Days on 0.5% CA diet

Fig. 3


A.
mdr1a-/- mdr1b-/- ♀
bsep-/- ♂
bsep+/- mdr1a+/- mdr1b+/- ♀
bsep+/- mdr1a+/- mdr1b+/- ♂
bsep+/- mdr1a-/- mdr1b-/- ♀
bsep+/- mdr1a-/- mdr1b-/- ♂
bsep-/-/mdr1a-/-/mdr1b-/-
♀ or ♂


B.
1 2 3 4 5 6
Mt, 480 bp
Wt, 460 bp
mdr1a
Mt, 480 bp
Wt, 387 bp
mdr1b
Wt, 305 bp
Mt, 207 bp
bsep

Fig.4



a.



Fig.5

b. Abcb1b transcript with exon 4 deletion

```
  1 atggagtttgaagagaaccttaagggaagagcagacaagaacttctcgaagatgggcaaaaagagtaaaaaggagaagaaagaaaagaaa
    M  E  F  E  E  N  L  K  G  R  A  D  K  N  F  S  K  M  G  K  K  S  K  K  E  K  K  E  K  K
 91 cctgctgttggcgtatttgggatggtggacccaacagtactctga (SEQ. ID NO:4)
    P  A  V  G  V  F  G  M  V  D  P  T  V  L  *   (SEQ. ID NO:5)
```

c. Abcb1b transcript with exons 4, 5, 6 deletion

```
  1 atggagtttgaagagaaccttaagggaagagcagacaagaacttctcgaagatgggcaaaaagagtaaaaaggagaagaaagaaaagaaa
    M  E  F  E  E  N  L  K  G  R  A  D  K  N  F  S  K  M  G  K  K  S  K  K  E  K  K  E  K  K
 91 cctgctgttggcgtatttgggatggaattggtgacaaaattgggatgtttttcagtccataa (SEQ. ID NO:6)
    P  A  V  G  V  F  G  M  E  L  V  T  K  L  G  C  F  F  S  P  *   (SEQ. ID NO:7)
```

Fig.6



Fig. 7


A. Infusion (100 μmol/kg) of 3α, 6α, 7α, 12α–tetrahydroxy-5β-cholan-24-oic acid
μl/min/100g BW
16.00
12.00
8.00
4.00
0.00
0.00
10.00
20.00
30.00
40.00
50.00
B. cholic acid infustion 100 μmol/kg
μl/min/100g BW
16.00
12.00
8.00
4.00
0.00
0.00
10.00
20.00
30.00
40.00
50.00
Time (minute)

Fig. 8


A.
B.
AU
0.60
0.40
0.20
0.00
10.00
20.00
30.00
Minutes
α-muricholate
β-muricholate
Taurocholate
7.550
9.267
9.767
23.483
Taurine-conjugated
6α, 7α THBA
unconjugated
6α, 7α THBA
7.483
9.400
9.950
24.117
34.467

Fig. 8C


Taurocholate
20.183
9.683
10.283
7.583
Minutes
AU
Taurocholate
Cholic acid
19.733
45.983
9.683
10.317
7.500
Minutes
AU


CHolic Acid 1
2g scale, yield 80%
Condition1. NBS,
NaHCO3, rt, 20h,
Condition 2, NBS,
NaHCO3,rt 17h,
then reflux 2h,
8g scale, Yield 95%
40g scale, Yield 95%
Step1
MeOH, HCl, reflux
8g scale, Yield: 66%,
35g scale, yield 65%
Step2
12
3
19g avilliable
Ac2O, Py, 40-50 °C, 2h
4'
Ac2O, Py, 70-80 °C, overnight
2g scale, 50% yield
Step 3
4
CH3COOH, Br2 in acetic acid,
20°C
Step 4
5
0.1g of 12 from 0.3g of 11, yield 30%
0.6g of 12 from 0.64g of 11, yield 81%
KOH, MeOH,
rt, overnigh
c i
Step 5
13
TSOH, MeOH,
rt, overnight
e ii
Step 6
14
20 g, 57%
NaBH4/ZnCl2
Et2O
15
12 g, 59%
KOH/CH3OH
Reflux
Step 8
7
9 g, 84%

Fig. 10


Ac2O, Py
Step a
AcO
OAc
OAc
OAc
16
20 g, 57%
DCCI,N-hydroxysuccinimide
taurine,NaHCO3,H2O
0.1N NaOH
HN
SO3H
OAc
17
12 g, 59%
1N NaOH
18
NaBH4/ZnCl2
Et2O
14
KOH/CH3OH
Reflux
Step 8
15
9 g, 84%
7

Fig. 11



Fig. 12


A.
wt male, 400 umol/kg BW
wt male, 350 umol/kg BW
wt male, 250 umol/kg BW
wt male, 6 β, 7αTHBA 65 µmol/kg BW
Bile flow (µl/100g/minute)
infusion
Time (minute)
B.
wildtypes, 6α 7α THBA 200 µmol/kg BW
wt male, 6α, 7α THBA 65 µmol/kg BW
Bile flow (µl/100g/minute)
infusion
Time (minute)
C.
wt male, 6α, 7α THBA 65 µmol/kg BW
wt male, 6 β, 7αTHBA 65 µmol/kg BW
wt male, UDC 65 µmol/kg BW (MTD)
Bile flow (µl/100g/minute)
infusion
Time (minute)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2010/001338

A. CLASSIFICATION OF SUBJECT MATTER
IPC: ***C07J 9/00*** (2006.01) , ***A61K 31/575*** (2006.01) , ***A61P 1/16*** (2006.01)
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC: ***C07J 9/00*** (2006.01) , ***A61K 31/575*** (2006.01) , ***A61P 1/16*** (2006.01)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
C07J, A61K

Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used)
STN, Canadian Patent Database, EPOQUE: biliary, bile, tetrahydroxylated, polyhydroxylated, cholic, cholanoic

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	WO 2009/105897 (BRITISH COLUMBIA CANCER AGENCY BRANCH), 3 September 2009, 03.09.2009, see whole application.	1-36
X	WO 2006/116814 (VANADIS BIOSCIENCE LTD), 9 November 2006, 9.11.2006, see claim 8.	1-4, 6-21, 23-36
Y	See paragraph [0044]	1-36
X	WO 2006/116815 (VANADIS BIOSCIENCE LTD), 9 November 2006, 9.11.2006, see claim 8.	1-4, 6-21, 23-36
Y	See paragraph [0040]	1-36
Y	IIDA, *et al.*, "Preparation of Glycine-conjugated Bile Acids and their Gas/Liquid Chromatographic Analysis on an Aluminum-clad Flexible Fused Silica Capillary Column", *Biomed. Chromatogr.*, **1992**, *6*(1), p4-8.	8-11, 25-28
Y	AGGARWAL, *et al.*, "Synthesis of 3α,6β,7α,12β- and 3α,6β,7β,12β-	4, 5, 21, 22

[ ] Further documents are listed in the continuation of Box C.

[X] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
15 September 2010 (15-09-2010)	25 November 2010 (25-11-2010)

Name and mailing address of the ISA/CA	Authorized officer
Canadian Intellectual Property Office Place du Portage I, C114 - 1st Floor, Box PCT 50 Victoria Street Gatineau, Quebec K1A 0C9 Facsimile No.: 001-819-953-2476	Karol Gajewski (819) 934-6734

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2010/001338

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of the first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons :

1. [X] Claim Nos. : 1-17, 37 (in part), 38 (in part)
because they relate to subject matter not required to be searched by this Authority, namely :

Claims 1-17, 37, 38 are directed to a method for treatment of the human or animal body by surgery or therapy which the International Search Authority is not required to search. However, this Authority has carried out a search based on the alleged effect or purpose/use of the product defined in claim 32.

2. [ ] Claim Nos. :
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically :

3. [ ] Claim Nos. :
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows :

1. [ ] As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claim Nos. :

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim Nos. :

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

[ ] The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

[ ] No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/CA2010/001338

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
WO2009105897A1	03 September 2009 (03-09-2009)	WO2009105897A1	03 September 2009 (03-09-2009)
		CA2716922 A1	03 September 2009 (03-09-2009)
WO2006116814A1	09 November 2006 (09-11-2006)	US2009074895A1	19 March 2009 (19-03-2009)
WO2006116815A1	09 November 2006 (09-11-2006)	US2009232913A1	17 September 2009 (17-09-2009)